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Clostridium difficile affects patients in hospitals and communities worldwide, is responsible for 
significant annual mortalities and represents a considerable economic burden on healthcare systems. 
This bacterium might also be carried asymptomatically in the gut, potentially leading to ‘silent’ onward 
transmission. Treatment has always been difficult, because the disease is both caused and resolved by 
antibiotic intake. The two main C. difficile virulence factors are toxins A and B, both of which are 
pro-inflammatory and enterotoxic in human intestine. Clinically relevant toxin A-negative/toxin 
B-positive strains that cause diarrhoea and colitis in humans have been isolated with increasing 
frequency worldwide, namely the multidrug resistant PCR-ribotype (RT) 017. Previous studies 
documented changes in C. difficile infection (CDI) epidemiology associated with the rapid emergence 
of antibiotic-resistant strains, highlighting the importance of antimicrobial susceptibility surveillance.  
The present work describes epidemiological and antimicrobial susceptibility data of C. difficile 
strains isolated in Portugal. A total of 378 C. difficile strains from 11 Portuguese hospital centres were 
characterized regarding toxin profile and RT, and part of these strains were also evaluated for its 
susceptibility to moxifloxacin, vancomycin, metronidazole, rifampicin and imipenem and determinants 
of antimicrobial resistance. Multilocus variable tandem repeat analysis (MLVA) and whole genome 
sequencing (WGS) analysis was also performed in a subgroup of epidemic, multidrug isolates. 
Most of the isolates were toxigenic (91.3%), of which 94.2% had both toxins A and B and 25.8% 
of them also had a binary toxin. Seventy-five different RTs were identified. RT027, RT014, RT106 and 
RT017 were the most frequently isolated. There was no evidence of resistance to vancomycin among 
the 183 tested strains, and reduced susceptibility to metronidazole was rare (2.2%). Resistance to 
moxifloxacin was evident in multiple RTs, and were mainly from RTs positive for the three toxins, 
RT027 (18/18), RT126 (8/9) and RT078 (6/12), except the RT017 (19/19), which is toxin 
A-negative/toxin B-positive. All moxifloxacin-resistant strains exhibited a known mutation in GyrA 
(Thr82Ile). Rifampicin resistance was found in 11.5% of the 183 strains tested, most from RT017 
(19/19) but also in one strain from RT241 and other from RT043. Most rifampicin-resistant strains 
harbour the previously described mutations in RpoB (His502Asn and Arg505Lys), although one 
mutation, Ser507Leu, found alone in a resistant strain was not previously described. Of the 181 strains 
belonging to 57 RTs tested for imipenem susceptibility, only strains from RT017 showing high level of 
resistance to this antibiotic (MIC > 32 mg/L). The resistance determinants, ermB and tetM genes were 
present in 34 (10.1%) and in 63 (20.12%) strains, respectively, being that 22 (6.5%) contained both 
genes. 
Twenty strains were toxin A-negative/toxin B-positive, 19 of them belonging to the well-known 
emerging RT017, 11 from hospital A isolated in a short period of time suggesting that an outbreak have 
occurred, the remaining eight from hospital B, isolated between 2016 and 2017, where this RT seems to 
be endemic. Overall, these strains were multiresistant, presenting resistance to six of the 10 antibiotics 
tested: moxifloxacin, rifampicin, imipenem, tetracycline, clindamycin and erythromycin (these two 
belonging to the MLSB group), with high level of resistance. PCR screening of the resistance 
determinants showed that all strains harboured the tetM gene, but only the eight strains from hospital B 
were positive for ermB. Analysis by WGS revealed the presence of the ermG gene in the 
ermB-negative/MLSB-resistant strains. This gene was found to be in a putative mobile element of 63 kb 
exclusive of the hospital A clonal cluster. Transformation of a susceptible strain (C. difficile 630Δerm), 
with a plasmid containing the ermG gene, proved that the presence of this gene provides high resistance 
to clindamycin and erythromycin in C. difficile. Mutations in penicillin-binding proteins were also 
observed in all imipenem resistant strains. Phylogenetic analysis of single nucleotide polymorphisms 
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(SNPs) of RT017 isolates collected from 2012 to 2017 revealed three clusters, each from a single hospi-
tal. Subtyping by MLVA was also applied to detect the clonal spread of C. difficile belonging to toxin 
A-negative/toxin B-positive, and the results were overall similar with the WGS analysis.  In addition, 
74 SNPs variations were found among RT017 strains, namely in proteins involved in antimicrobial 
resistance and in hypothetical proteins. 
The current work gives a contribution to the knowledge of the molecular epidemiology and 
resistance patterns of C. difficile in Portugal. The results presented herein alert to the presence of 
multidrug resistant strains of RT017 in Portuguese hospitals in endemic and outbreak situations, and 
indicates the need for adequate use of antimicrobial agents, especially carbapenems, whose resistance 
was only observed among the strains of this emerging RT. The lineage of strains from RT017 appears 
to be constantly evolving, acquiring new resistance determinants, which highlights the need for 
continued epidemiological and antimicrobial surveillance. 
The wide variety of RTs found suggests that there are other routes of transmission beyond 
nosocomial transmission, raising concern about the epidemiological change in this pathogen. As such, 
other potential sources, particularly in animals, which may also act as a reservoir for C. difficile and 
antimicrobial resistance determinants, should be investigated in the future. 
Finally, this study provides the basis for investigating important factors for the spread and 
persistence of toxin A-negative/toxin B-positive strains, such as studies on the importance of proteins 
that distinguish these strains, namely the hypothetical proteins. 
 
Keywords: Clostridium difficile infection, molecular epidemiology, antimicrobial susceptibility, 
resistance determinants, ribotype 017.  




Clostridium difficile é uma bactéria Gram-positiva, anaeróbia estrita e formadora de esporos, 
que coloniza o cólon. A infeção por C. difficile (ICD) encontra-se principalmente associada ao meio 
hospitalar e consumo recente de antibiótico, representando um fardo económico considerável para os 
sistemas de saúde. No entanto, este quadro tem estado a alterar-se, verificando-se um acréscimo na 
incidência de infeção em populações anteriormente pensadas em baixo risco e sem contacto prévio com 
o ambiente hospitalar. Esta bactéria foi descoberta em 1935 como parte da microdiota intestinal normal 
de recém-nascidos, no entanto, a sua importância em doenças em humanos só foi identificada mais tarde, 
na sequência de múltiplos trabalhos conduzidos na década de 1970, quando esta patologia se tornou 
mais frequente devido ao aumento no consumo de antibióticos. 
O espectro da doença clínica varia de diarreia leve a megacólon tóxico, perfuração do colón e 
morte. No entanto, esta bactéria também pode ser transportada de forma assintomática no intestino, 
potencialmente levando a transmissão silenciosa. O tratamento da ICD sempre foi difícil, porque a 
doença é causada e resolvida pela toma de antibióticos. Até a recente introdução da fidaxomicina, o 
tratamento estava limitado a toma de metronidazol e vancomicina.  
Nos últimos anos, a ICD surgiu como uma doença proeminente devido a um aumento súbito na 
ocorrência de surtos, acompanhada por um aumento da gravidade da doença e mortalidade. Esta 
alteração foi principalmente associada à disseminação de uma estirpe epidémica denominada ribotipo 
(RT) 027, principalmente caracterizada por uma elevada resistência às fluoroquinolonas, cujo pico de 
consumo coincidiu com o início da sua propagação epidémica. Ao mesmo tempo, porém, outras estirpes 
também começaram a emergir com maior virulência. 
Os dois principais fatores de virulência, e responsáveis pelo desenvolvimento da doença, são as 
toxinas A e B, ambas pró-inflamatórias e enterotóxicas no intestino humano, algumas estirpes são 
também caracterizadas pela produção de uma toxina binária. No entanto estirpes de C. difficile 
clinicamente relevantes com fenótipo toxina A-negativa/toxina B-positiva que causam diarreia e colite, 
têm sido isoladas com maior frequência em todo o mundo, nomeadamente pertencentes ao RT017, 
resistentes a múltiplos antibióticos.  
Embora os agentes antimicrobianos sejam fatores de grande relevância para o desenvolvimento 
da ICD, a resistência da bactéria não é um pré-requisito para tal, podem sim antecipar uma rápida 
disseminação dessas estirpes resistentes em ambiente hospitalar, uma vez que um fenótipo de resistência 
pode conferir uma vantagem seletiva significativa dentro do ecossistema intestinal, facilitando o on-set 
da ICD logo no início da toma de antibióticos. Deste modo, em termos de prevenção da ICD, é 
imperativo limitar a propagação de estirpes resistentes de C. difficile, para tal, uma vigilância de 
fenótipos e genótipos de resistência é essencial. 
O presente trabalho tem como objetivo fornecer informação atualizada relativamente à 
epidemiologia molecular e suscetibilidade antimicrobiana de estirpes de C. difficile isoladas de hospitais 
Portugueses. Para esse fim, um total de 378 amostras de fezes (correspondentes a 374 pacientes 
diagnosticados com ICD) provenientes de 11 centros hospitalares portugueses foram sujeitas a cultura 
anaeróbica. As estirpes de C. difficile isoladas destas amostras foram caracterizadas em relação ao perfil 
de toxinas e RTs; um subgrupo dessas estirpes foi também avaliado quanto à suscetibilidade à 
moxifloxacina, vancomicina, metronidazol, rifampicina e imipenemo. Alguns determinantes de 
resistência foram também estudados. 
A maioria dos isolados eram toxigénicos (91,3%), dos quais 94,2% apresentavam as toxinas A 
e B sendo que 25,8% desses também possuíam a toxina binária; no total 33 estirpes eram 
Molecular epidemiology and antibiotic resistance of Clostridium difficile: 
VI 
não-toxigénicas. Foram identificados 75 RTs diferentes, sendo os RTs mais frequentes o RT027 
(13,8%), RT014 (8,2%), RT106 (6,1%) e RT017 (5,1%). Não houve evidência de resistência à 
vancomicina entre 183 estirpes toxigénicas testadas, a menor suscetibilidade ao metronidazol também 
foi rara verificando-se em apenas 4 estirpes (2,2%). A resistência à moxifloxacina foi evidente em 
múltiplos RTs, 55 de 183 (30,1%) estirpes testadas apresentaram resistência, pertencentes 
principalmente a RTs positivos para três toxinas, RT027 (18/18), RT126 (8/9) e RT078 (6/12), exceto 
o RT017 (19/19), toxina A-negativa/toxina B-positiva. Todas as estirpes resistentes à moxifloxacina 
continham uma mutação já descrita na GyrA (Thr82Ile). A resistência à rifampicina foi encontrada em 
11,5% das 183 estirpes testadas, na sua maioria do RT017 (19/19), mas também numa estirpe do RT241 
e uma do RT043. A maioria das estirpes resistentes à rifampicina continham mutações na RpoB já 
descritas (His502Asn e Arg505Lys); a mutação, Ser507Leu, descrita neste trabalho pela primeira vez, 
foi a única encontrada numa estirpe resistente do RT043. De 181 estirpes, pertencentes a 57 RTs 
diferentes, testadas quanto à suscetibilidade ao imipenemo, apenas as estirpes do RT017 (19/19) 
apresentaram resistência a este antibiótico com alto nível de resistência (concentração mínima inibitória 
≥ 32 mg/L). Os genes ermB e tetM, determinantes da resistência aos MLSB e à tetraciclina, 
respetivamente, estavam presentes em 34 (10,1%) e 68 (20,12%) das estirpes testadas, respetivamente, 
sendo que 22 estirpes (6,5%) continham ambos os genes; a maioria das estirpes (258/338) não continham 
nenhum destes genes nomeadamente, as estirpes do RT027 (40/41). O gene catD, que confere resistência 
ao cloranfenicol, não foi encontrado em nenhuma estirpe. 
Foram identificadas 20 estirpes toxina A-negativa/toxina B-positiva, 19 delas pertencentes ao 
RT emergente RT017, 11 do hospital A isoladas num curto período de tempo sugerindo que ocorreu um 
surto, as oito restantes do hospital B, isoladas entre 2016 e 2017 onde esta estirpe parece ser endémica. 
No geral, essas estirpes revelaram-se multi-resistentes, apresentando resistência a seis dos 10 
antibióticos testados: moxifloxacina, rifampicina, imipenemo, tetraciclina, clindamicina e eritromicina 
(os dois últimos pertencentes ao grupo MLSB). A triagem por PCR dos determinantes de resistência 
mostrou que todas possuíam o gene tetM, mas apenas os oito isolados do hospital B eram positivos para 
o ermB. A análise dos dados gerados por sequenciação total do genoma (WGS) das estirpes 
ermB-negativas/MLSB-resistentes revelou a presença do gene ermG, pela primeira vez descrito em 
estirpes clínicas toxigénicas de C. difficile. Este gene foi encontrado num putativo elemento móvel de 
63 kb e somente nas estirpes associadas ao surto no hospital A. Foi possível verificar que este gene está 
associado a um alto nível de resistência à clindamicina e eritromicina em C. difficile através da inserção 
de um plasmídeo contendo o ermG em uma estirpe sensível (C. difficile 630Δerm). Outros genes 
associados a resistências foram também encontrados neste elemento móvel, como os genes mefA e msrD 
que conferem resistência aos macrólidos, e um gene que codifica para uma estreptogramina A 
acetiltransferase que confere resistência à estreptogramina A em outras bactérias, no entanto este grupo 
de antibióticos não foi aqui testado. Também foram observadas mutações em genes que codificam para 
as proteínas de ligação à penicilina (PBPs) nas estirpes resistentes ao imipenemo; estas mutações 
localizam-se próximo dos motivos conservados da PBP1 (Ala555Thr) e da PBP3 (Tyr721Ser).  
A análise filogenética de polimorfismos de nucleotídeos únicos (SNPs) de isolados do RT017 
obtidos de 2012 a 2017 revelou a existência de três grupos clonais, cada um com isolados de um único 
hospital. A análise de multilocus variable number tandem repeat (MLVA) também foi aplicada para 
detetar a disseminação clonal de C. difficile toxina A-negativa/toxina B-positiva, e os resultados foram 
concordantes com a análise de WGS. Além disso, 74 variações de SNPs foram encontradas entre as 
estirpes do RT017, compreendendo mutações sinónimas e não-sinónimas, nomeadamente em proteínas 
envolvidas em resistência a antimicrobianos e em proteínas hipotéticas. 
Em conclusão, embora grande parte do foco de C. difficile tenha sido o RT027, novas estirpes 
virulentas continuam a emergir, o que requer consideração na vigilância futura. Os resultados aqui 
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apresentados alertam para a presença de estirpes multirresistentes do RT017 nos hospitais portugueses, 
sugerindo um potencial epidémico para as mesmas. A presença destas estirpes multirresistentes indica 
a necessidade de uma utilização adequada dos agentes antimicrobianos, nomeadamente dos 
carbapenemos, cuja resistência só foi observada entre as estirpes deste RT. A linhagem das estirpes do 
RT017 parece estar em constante evolução, adquirindo novos determinantes de resistência, o que realça 
a necessidade de uma vigilância epidemiológica e antimicrobiana contínua, bem como a imposição de 
medidas de prevenção da transmissão de C. difficile no contexto hospitalar, nomeadamente através do 
diagnóstico e tratamento de todos os pacientes com ICD e restrição de alguns antibióticos. 
Contudo, a grande variedade de RTs encontrada no geral, sugere que existem outras vias de 
transmissão para além da transmissão nosocomial, suscitando preocupação com a mudança na 
epidemiologia deste agente patogénico. Como tal, outras potenciais fontes de infeção, nomeadamente 
em animais, que também podem atuar como um reservatório de C. difficile e de determinantes da 
resistência antimicrobiana, devem ser investigadas futuramente. 
Por fim, este estudo proporciona a base para investigar fatores importantes para a disseminação 
e persistência de estirpes toxina A-negativa/toxina B-positiva, como por exemplo estudos futuros sobre 
a importância das proteínas que distinguem estas estirpes, nomeadamente as proteínas hipotéticas.  
 
Palavras-chave: Infeção por Clostridium difficile, epidemiologia molecular, suscetibilidade aos 
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1. Introduction    
1.1. Clostridium difficile, the organisms and infection cycle    
Clostridium difficile is a Gram-positive bacterium, strict anaerobe, frequently implicated in 
cases of nosocomial diarrhoea. The infection is caused by toxigenic strains, although there are naturally 
non-toxin producing strains capable of colonizing their hosts (Martin, Monaghan, & Wilcox, 2016). 
C. difficile was recently renamed as Clostridioides difficile (Lawson, Citron, Tyrrell, & 
Finegold, 2016), however the still more familiar designation of C. difficile will be used throughout the 
present document.   
This bacterium was initially identified in 1935 as part of the normal gut microbiota of neonates 
(Hall & O’Toole, 1935). The spectrum of C. difficile-associated disease varies from mild diarrhoea to 
severe colitis, and it may lead to toxic megacolon, perforation of the colon, sepsis and death. Its 
association with disease was not described until the 1970s following several studies. In those studies, a 
causal effect of antibiotic exposure and gut diseases was also demonstrated as patients receiving 
antibiotic treatment developed pseudomembranous colitis (Bartlett, Chang, Gurwith, Gorbach, & 
Onderdonk, 1978; Tedesco, Barton, & Alpers, 1974). 
C. difficile is a spore-forming bacterium, which, in turn, is able to tolerate extreme conditions 
that the vegetative form cannot, assuming an essential role in the transmission of the pathogen, as well 
as in environmental persistence. In this way, the spores are considered as the infectious form, since they 
allow the survival of the microorganism in the acidic environment of the stomach of the host. Upon 
reaching the duodenum, the spores get into contact with bile acids which along with glycine and some 
other cofactors initiate germination (Howerton, Ramirez, & Abel-Santos, 2011; Janoir et al., 2013).   
The organism is transmitted from person to person by the fecal-oral route. The cycle of C. 
difficile infection (CDI) begins with an uncolonized individual who is exposed to bacterial spores. Then, 
upon a disturbance of the normal gut microbiota, occurs the colonization and proliferation of C. difficile. 
The infected individual will also be spore excretor, restarting the infectious cycle. The resulting 
vegetative cells then penetrate the mucus layer and adhere to intestinal epithelial cells (Martin et al., 
2016).  
Several factors can lead to modification of the intestinal microbiota, such as surgical incisions, 
nasogastric tube feeding and medication intake. Antibiotic therapy is the major risk factor for CDI 
because it disrupts the microbial community in the gut that forms a protective barrier, thus weakening 
resistance to colonization (Dharmarajan, Sipalay, Shyamsundar, Norkus, & Pitchumoni, 2000; Manges 
et al., 2010). 
Pultz and Donskey (2005) have demonstrated that antibiotics can influence the growth of C. 
difficile in different ways depending on its activity against the pathogen and the extent to which the 
agent disrupts the gut microbiota; CDI can be virtually triggered by any antibiotic, as it promotes 
damaged in the protective microbiota. However, if the strain of C. difficile is resistant to the antibiotic 
taken it has an additional selective advantage. This is because, even in susceptible strains, the formation 
of spores allows the bacteria to persist in the gut, germination only occurs when the drug is no longer 
present at levels sufficient to inhibit growth and multiplication of C. difficile. But resistant strains can 
germinate while the therapy is in progress, so they have an advantage in their spread due to the use of 
antibiotics (Coia, 2009). In fact, mounting evidence suggests that antibiotic resistance is a key player in 
the epidemiology of CDI (Gerding, 2004). Fluoroquinolone prescribing correlated highly with incidence 
of CDI cause by fluoroquinolone-resistant strain, having been observed decline in incidence of CDI 
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after restriction of this antibiotic (Dingle et al., 2017). Therefore, it is essential to monitor the resistance 
profile of this microorganism.  
1.2. Virulence factors    
The main virulence factors associated with C. difficile infection are two large enteric toxins, A 
and B toxins, whose action on the colonic intestinal epithelium are responsible for an intense 
inflammatory response causing acute inflammation of the large intestine. Those toxins are encoded by 
two genes, tcdA and tcdB situated on the C. difficile chromosome in a 19.6 kilobase (kb) pathogenicity 
locus (PaLoc), that also contains three additional regulatory genes, tcdR, tcdC and tcdE (Kuehne et al., 
2010). TcdR is a sigma factor that facilitates the binding of RNA polymerase to the promoters of the 
tcdA and tcdB genes, therefore promoting toxin production (Mani & Dupuy, 2001); TcdC is an 
TcdR-specific anti-sigma factor that appears to negatively regulate toxin A and B expression through 
disruption of TcdR interaction with RNA polymerase (Matamouros, England, & Dupuy, 2007); finally, 
tcdE encodes a protein that has similarity to phage holin involved in toxin secretion (Govind & Dupuy, 
2012). 
Both toxins A and B catalyse the glucosylation and, hence, inactivation of Rho protein family 
of GTPases in intestinal epithelial cells, mediating disorganization of the cell cytoskeleton and cell 
death. Structurally these toxins have three other domains: i) the cysteine protease domain,  involved in 
the autocatalytic processing of the toxin protein that releases the enzymatic domain in the cytosol after 
receptor-mediated endocytosis; ii) the translocation domain that mediates entry of the toxin into the 
target cell cytoplasm; iii) the receptor-binding domain, responsible for binding to and the uptake into 
the target cell (Just & Gerhard, 2004; Reineke et al., 2007). 
Several studies tried to figure out the relative contributions of both toxins in the pathogenesis; 
toxin A alone was first believed to induce most of the pathology observed after infection, but Lyras et 
al. (2009) using isogenic tcdA and tcdB mutants in a hamster model showed that, in fact, toxin B is 
essential for virulence while toxin A is dispensable. However the studies conduct by Kuehne et al. (2010) 
using a similar method re-establish the importance of both toxins A and B in CDI, since they reveal to 
be important mediators of in vitro cytotoxicity and in vivo virulence. Many factors differentiate both 
studies which could lead to different interpretations. Although both groups used derived strains of C. 
difficile 630, these strains had been separately passaged numerous times over a long period of time (>15 
years) and there may be genetic differences between them, in fact, the strain used by Kuehne et al. (2010) 
produces significantly more toxin A than the equivalent strain used in the earlier study (Carter, Awad, 
Kelly, Rood, & Lyras, 2011; Lyras et al., 2009). The end points used to determine the in vivo 
pathogenicity of the strains were also different in both studies. Death was an endpoint for Lyras et al. 
(2009) study, by contrast a clinical scoring system comprising weight loss, behavioural changes, and 
wet tail, followed by sacrifice of moribund and sick animals, was used by Kuehne et al. (2010).  In any 
case, both toxins are essential for disease because non-toxigenic strains are avirulent (Kuehne et al., 
2010).  
Some strains of C. difficile only produce a functional toxin B, due to deletion in the repetitive 
region of tcdA gene (tcdA-/tcdB+). Studies showed that, toxin B from those strains is able to modify 
more substrates than wild-type toxin B from toxin A-positive/toxin B-positive (tcdA+/tcdB+) strains due 
to polymorphisms in its tcdB gene, giving rise to altered glucosylation of Rho proteins and inducing a 
cytopathic effect on cells (Chaves-Olarte et al., 1999; Rupnik, Kato, Grabnar, & Kato, 2003).   
In addition to these two toxins, some strains produce a binary toxin known as C. difficile 
transferase (CDT), encoded by two genes, cdtA and cdtB, and located in a different locus, the Binary 
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Toxin Encoding Locus. CDT induces redistribution of microtubules and formation of long 
microtubule-based protrusions at the surface of intestinal epithelial cells that increase bacterial 
adherence; this toxin also causes death of beneficial eosinophils that would play an important role in 
promoting a healthy immune response during infection (Cowardin et al., 2016; Schwan et al., 2009).  
Although the toxins are regarded as the primary virulence factors, other factors intervene in the 
pathogenic process, notably to allow the establishment of the bacterium in its colonic niche, such as the 
sporulation. Since C. difficile is a strict anaerobe, its virulence is linked to the ability to form spores, 
being these able to survive in aerobic environments and resist to cleaning measures and disinfection 
agents (Dawson, Valiente, Donahue, Birchenough, & Wren, 2011; Janoir et al., 2013).   
1.3. Epidemiology changing and risk factors 
CDI is primarily regarded as a healthcare-related disease that is most prominent among the 
elderly population, representing a huge clinical and economic burden. This is most likely due to a 
reduced immune status, concomitant comorbidities and several hospitalizations as these increases the 
risk of exposure to the microorganism and clinical outcome (Dharmarajan et al., 2000). Also, this 
population is more prompt to take antibiotics, which are the main risk for CDI.  Use of drugs that reduce 
gastric acid (such as proton pump inhibitors) also increase the likelihood of infection (Janarthanan, 
Ditah, Adler, & Ehrinpreis, 2012). However, in the past years, the proportion of CDI occurring in 
patients outside the hospital setting has increased, targeting also healthy young people and peripartum 
women, two groups previously thought to be at low risk (Centers for Disease Control and Prevention, 
2005; van Dorp et al., 2017). C. difficile is very widespread in the environment, and can be found in 
diverse reservoirs such as soils, river waters, lakes, and also in various animal, such as animals in the 
food chain (cattle, pigs) and also in pets (Álvarez-Pérez, Blanco, Harmanus, Kuijper, & García, 2017; 
Thitaram et al., 2016); a genomic similarity has been found between strains isolated from humans and 
from animals, mostly pigs (Janezic, Ocepek, Zidaric, & Rupnik, 2012; Knight, Squire, Collins, & Riley, 
2017).   
Changing C. difficile epidemiology is noted worldwide and is variable across countries, 
particularly in relation to prevalent strains and its antimicrobial resistance pattern. Historically low rates 
of severe disease and death (3% or less) may have led to an under estimation of the importance of C. 
difficile-associated disease as a healthcare-associated infection (McDonald et al., 2005); nowadays, on 
average, seven CDI cases occur for every 10,000-overnight patient stays in European hospitals, making 
it the most commonly reported pathogen associated with hospital-associated gastrointestinal disease in 
Europe (Davies et al., 2014). In the United States a population-based study by Lessa et al. (2015) 
estimated almost a half million cases in 2011, with 83,000 recurrences and 29,300 deaths, while the 
National and State Healthcare Associated Infections progress report, based on 2014 data, that CDI 
incidence is higher than methicillin resistant Staphylococcus aureus (MRSA) incidence in U.S., and 
although an 8% decrease in CDI has been observed between 2011 and 2014, U.S. hospitals reported a 
significant increase in CDI between 2013 and 2014 (Centers for Disease Control and Prevention, 2016).  
This shift in epidemiology has been noted from 2,000 onwards, when there was a further increase on 
number and severity of CDI, with higher transmission rates and greater mortality, mainly due to the 
spread of PCR-ribotype (RT) 027. This epidemic strain is characterized by high resistance to 
fluoroquinolones, whose peak of consumption in North America coincides with the beginning of its 
epidemic spread (McDonald et al., 2005; Muto et al., 2005; Pépin, Valiquette, & Cossette, 2005).  
In Portugal the first CDI outbreak was reported in 2014 with a mortality rate of 11.3%, been 
attributed to the RT027 that was also reported as the  most frequent  RT in  the country, mainly due to 
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healthcare facility-associated cases (Oleastro et al., 2014; Santos et al., 2016). 
Although the increased rates of CDI have been primarily attributed to RT027, CDI cases 
attributed to other emerging RTs, such as RT017 have been reported worldwide (Dobreva et al., 2013; 
Drudy, Harnedy, Fanning, Hannan, & Kyne, 2007; Lee, Lee, Lee, Riley, & Kim, 2014). 
1.4. Toxin A-negative/toxin B-positive ribotypes 
A number of tcdA-/tcdB+ RTs have been identified to date (Rupnik et al., 2003), but the most 
clinically significant is RT017 (also known as toxinotype VIII) that is been isolated with increasing 
frequency worldwide.  
The first RT017 outbreak reported occurred in a Canadian hospital in 1998 over a three month 
period (Alfa et al., 2000). Since that time, cases associated with this RT have been described by other 
groups. In Poland between 2004 and 2006 and in Bulgaria between 2008 and 2012, RT017 was identified 
to be the most prevalent, infecting 44 and 28% of the patients, respectively (Dobreva et al., 2013; Pituch 
et al., 2011).  
This trend is also observed in Asia, where RT017 is one of the most prevalent RTs. A Korean 
study, where sampling was performed over a 10-year period, showed that RT017 was the most dominant 
strain type among hospitalized patients during 2004–2008. These results coincided with the initial use 
of imipenem and moxifloxacin at the hospitals, making it feasible that the introduction of these drugs 
would be related to the emergence of this RT, once the resistance levels among their RT017 isolates 
were 12 and 85% for these drugs, respectively. Additionally, they were also resistant to clindamycin, 
erythromycin and ciprofloxacin (Lee et al., 2014).  
In other studies, the increased prevalence of RT017 strains has also been associated with 
increased antibiotic resistance. Among the RT017 Polish isolates, 86.8% were resistant to imipenem 
and 91% were erythromycin-resistant whereas only 7% of the other RTs with the most common toxin 
profile (tcdA+/tcdB+) exhibited resistance to this antibiotic (Pituch et al., 2011). Isolates from an 
outbreak in Ireland were all resistant to multiple antibiotics including macrolides, lincosamide and 
newer classes of fluoroquinolones (Drudy et al., 2007). In Portugal RT017 is one of the most common 
RTs, having been isolated endemic multidrug resistant strains in one hospital (Isidro et al., 2017; Santos 
et al., 2016).  
Although RT017 strains are negative for the toxin A encoding gene tcdA, they are capable of  
causing the full spectrum of clinical illness usually associated with tcdA+/tcdB+ strains (ranging from 
asymptomatic colonization through to severe disease), and cases of fulminant colitis have been 
documented (Alfa et al., 2000; Arvand, Hauri, Zaiss, Witte, & Bettge-Weller, 2009; Drudy et al., 2007). 
The C. difficile strain M68 is the representative strain of the RT017, and has the full genome 
sequenced. The tcdA gene of this type strain contains a 1.8 kb deletion at the 3′ end and a nonsense 
mutation at the amino acid 47 (He et al., 2010; Rupnik et al., 2003).  
1.5. Diagnosis and treatment 
There are many differences in CDI surveillance systems, infection detection and laboratory 
diagnosis between and within countries (Davies et al., 2014). Two reference tests are available, the cell 
cytotoxicity neutralization assay (CCNA) and toxigenic culture (TC). TC demonstrates the presence of 
C. difficile isolates with the ability to produce toxin when cultured, while CCNA detects the presence of 
toxin in stool samples. Both these techniques are however time consuming, 
requiring specialized staff and equipment. Therefore, in hospital laboratories other standards tests are 
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often used for patients with diarrhoea, such as the toxin A/B commercial enzyme immunoassay (EIA) 
that directly detects C. difficile toxins in stool samples or EIAs that detect the glutamate dehydrogenase 
(GDH), an enzyme that is produced by both toxigenic and non-toxigenic strains. Nucleic acid 
amplification tests (NAAT), such as PCR assay and loop-mediated isothermal amplification of DNA, 
targeting toxin genes, are also used. However, all these tests have poor diagnostic accuracy as single 
tests and are no longer recommended as a stand-alone test to diagnose CDI (Crobach et al., 2016; 
Planche et al., 2013).  
One strategy to overcome this problem is to use two- or three-step screening algorithms. In this 
approach, an initial test is performed, which can be GDH EIA or nucleic acid amplification tests 
(NAAT), and if negative, specimens are reported as negative with no further testing done. Positive 
specimens must undergo additional testing for C. difficile by toxin A/B EIA and eventually for TC or 
NAAT (in case first test was a GDH EIA test) when toxin A/B EIA result is negative (Crobach et al., 
2016). 
Because many cases of CDI are hospital acquired, once CDI is diagnosed in a patient immediate 
implementation of appropriate infection control measures such as appropriate handwashing, gloving and 
improved environmental decontamination is mandatory to prevent further spread within the hospital 
(Vonberg et al., 2008).  
The mainstay of treatment is discontinuation of the offending antibiotic and administration of 
metronidazole or vancomycin; oral metronidazole is indicated in cases of mild to moderate disease, oral 
vancomycin for serious CDI, and combination therapy with enteral (oral/intracolonic) vancomycin and 
intravenous metronidazole in cases of ileus or toxic megacolon. When oral treatment is not possible, 
parenteral metronidazole is recommended, preferably combined with intracolonic or nasogastric 
administration of vancomycin. For severe, complicated and recurrent CDI cases, treatment with 
fidaxomicin is recommended, and has been found to be at least as effective as vancomycin and may be 
more effective for achieving symptomatic cure, since also targets the spores of C. difficile. Faecal 
transplantation following antibiotic treatment with an oral glycopeptide is reported to be highly effective 
in treating multiple recurrent CDI. For relapsing CDI, rifaximin use is also proposed as a chaser therapy 
(Debast et al., 2014; Nelson, Suda, & Evans, 2017). 
1.6. Antimicrobial susceptibility and mechanisms of resistance  
Apart from the classic virulence determinants, other factors, such as antibiotic resistance, 
promotes increased pathogenicity and spread of C. difficile strains. This pathogen presents an enormous 
capacity of adaptation to the environment, being able to become resistant to multiple drugs through 
metabolic and genetic alterations, which includes mutations in specific genes and gene acquisition. In 
fact, in a study conducted in 14 European countries, 47% of the strains analysed were resistant to at least 
one antibiotic and multidrug resistant was observed among the predominantly RTs as result of 
antibiotic-selective pressure (Spigaglia et al., 2011). 
Antibiotic resistance may be generated by different mechanisms and the surveillance of those 
different mechanisms and respective susceptibility patterns, for drugs frequently used in hospital 
environment and in the community, are needed.  
The resistance mechanism for vancomycin, the first-line of treatment for severe CDI, is still 
unclear, with only a few strains reported with reduced susceptibility to this drug (Freeman et al., 2015). 
In in vitro studies, C. difficile mutants exhibiting decreased susceptibility to vancomycin harboured 
mutations leading to a P108L substitution in murG gene, responsible for the conversion of lipid I to lipid 
II during the stage of peptidoglycan biosynthesis where the antibiotic acts, which could lead to antibiotic 
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resistance. Nonsense mutation in an RNA/single-stranded DNA exonuclease (homologous locus tag 
CD630_3659 in C. difficile 630), missense mutation causing a Asp244Tyr substitution in the β-subunit 
of RNA polymerase (encoded by rpoC) and a single amino acid deletion in L-serine dehydrogenase 
(encoded by sdaB) were also observed in those mutants (Leeds, Sachdeva, Mullin, Whitney Barnes, & 
Ruzin, 2014).  
C. difficile strains showing resistance to metronidazole are rare and when observed, the 
phenotype has been transient and lost after exposure of the bacteria to freeze. Therefore, the 
investigation of resistance mechanisms has proved to be difficult. Studies suggest that different C. 
difficile strains resistant to metronidazole can show peculiar alterations in their enzymes or metabolic 
pathways, such as decrease in the concentration of aminoacyl-tRNAs proteins, which likely result in 
post translational variations of proteins relevant for metronidazole activation, increased expression of 
proteins involved in DNA repair and variations in the electron transport, that could lead to alterations in 
both the energy production and intracellular redox potential, which influences the efficiency of 
metronidazole entry in the bacterial cell (Lynch et al., 2013; Moura et al., 2014). 
Genetic mutations are involved in resistance to both fluoroquinolones and rifamycin. Resistance 
to fluoroquinolones in C. difficile is due to point mutations in the quinolone-resistance determinant 
region (QRDR) of GyrA or GyrB, the DNA gyrase subunits target of these agents. Several amino acid 
substitutions have been identified in both GyrA and/or GyrB among moxifloxacin-resistant strains 
(Spigaglia et al., 2008). Rifamycin’s are a class of antibiotics including rifampicin that inhibit the RNA 
synthesis. Resistance to this group of antibiotics are associated with point mutations in rpoB, the gene 
encoding for the β-subunit of RNA polymerase, thus changing the antibiotic target and preventing its 
action (Curry et al., 2009). Resistance rates varied by geographic locations (Freeman et al., 2015), 
however rifamycin agents have been proposed as therapy for treatment of relapsing CDI (Debast et al., 
2014).   
Recently, mutations in two high-molecular-weight (HMW) penicillin-binding proteins (PBPs) 
were suggest as being involved in imipenem resistance in C. difficile strains (Isidro et al., 2017). This 
carbapenem antibiotic binds to PBPs inhibiting peptidoglycan synthesis, so these mutations would affect 
the antibiotic binding to its targets. Reports of imipenem resistance have been attributed to RT017 strains 
which have an additional PBP that could also play an important role in carbapenem resistance (Isidro et 
al., 2017; Lee et al., 2014).  
Resistance to macrolide-lincosamide-streptogramin B (MLSB) group of antibiotics is a common 
phenotype in certain RTs, most notable among RT017, RT001, RT012, RT046, RT126 , RT053, and 
RT078 (Freeman et al., 2015; Tenover, Tickler, & Persing, 2012). In C. difficile, MLSB is highly related 
to the presence of the ermB gene carried by mobile elements (Spigaglia & Mastrantonio, 2004). The 
ermB gene encodes for an rRNA methyltransferase that catalyse the methylation of specific adenine 
residue in 23S rRNA, altering the antibiotic binding site (Leclercq, 2002). However, ermB was not 
identified in all C. difficile clinical strains expressing high-level resistance to either erythromycin or 
clindamycin, two antibiotics belonging to MLSB group (Nyc et al., 2016; Spigaglia et al., 2011).   
Recently, a cfr-like gene named cfrC was described in C. difficile strains, and appears to be 
associated with a transposon similar to Tn6218, a novel Tn916-like transposon (Candela, Marvaud, 
Nguyen, & Lambert, 2017; Marín et al., 2015). This gene encodes for a 23S rRNA methyltransferase 
which causes C-8 modification in A2503 located in the peptidyl transferase region of bacterial ribosome, 
which modifies the antibiotic target. This mechanism confers resistance to several antimicrobial classes 
comprising phenicol’s (as chloramphenicol), oxazolidones and pleuromutilins, lincosamides and 
streptogramin A drugs (Candela et al., 2017). 
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Besides the cfr-like gene, chloramphenicol resistance is usually due to the presence of the catD 
gene, which encodes for a chloramphenicol acetyltransferase (CAT) inactivating the antibiotic, and is 
usually located in the Tn4451/Tn4453 transposons family (Spigaglia et al., 2011). This phenotype is not 
very common in C. difficile clinical strains, varying between countries (Freeman et al., 2015). 
Resistance to tetracycline in C. difficile is also related to a transposon-associated resistance 
determinant, which is, in most of the cases, the tetM gene, encoding for a ribosomal protection protein 
that binds to the ribosome and thereby preventing the drug from attaching to its binding site (Dönhöfer 
et al., 2012; Spigaglia, Carucci, Barbanti, & Mastrantonio, 2005).  In C. difficile, tetM is usually found 
on conjugative Tn916-like elements and Tn5397 (Spigaglia et al., 2005). These two transposons 
functionally differ from each other by its integration/excision module; Tn5397 harbours the tndX gene 
that appears to encode a member of the large resolvase family of site-specific recombinases. The Tn916 
harbours the the int and xis genes that are required for its excision and integration (Spigaglia et al., 2005; 
H. Wang et al., 2000). The widespread use of tetracyclines during the past 60 years has led to an increase 
in acquired tetracycline resistance determinants among clinically important pathogenic bacteria, making 
important to study the susceptibility pattern of this antibiotic (Dönhöfer et al., 2012). In C. difficile, 
resistance to tetracyclines varies widely between countries and with RT. In a European study published 
in 2007, tetracycline resistance was observed in C. difficile in isolates from the UK and the Netherlands, 
14.3% resistance in isolates from Poland, 21.4% resistance in isolates from Hungary, and 38.9% 
resistance in isolates from Greece; compared to 9.2% across the entire study (Barbut et al., 2007). 
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2. Aims and objectives  
C. difficile is well recognized as the leading cause of antibiotic-associated diarrhoea, having a 
significant impact in both healthcare and community settings. In view of this situation, knowledge about 
the circulation dynamics of different strains in Portugal is of great importance. Modern technologies, 
such as whole-genome sequencing and multilocus variable number tandem repeat analysis, are helping 
to track C. difficile transmission.  
In order to contribute to the knowledge about the current paradigm of CDI in the country, it was 
intended with this work to accomplish the following objectives: 
(i) Identify and characterize strains isolated from Portuguese hospitals, through phenotypic and 
molecular techniques, namely the identification of predominant RTs and detection of main 
virulence factors;  
(ii) Evaluate antimicrobial susceptibility patterns, identify mechanisms of resistance and investigate 
possible associations of specific genotypes with antimicrobial resistance phenotypes;  
(iii) Evaluate the frequency of toxin A-negative/toxin B-positive strains and their epidemiological 
characteristics; 
(iv) Perform a molecular study in order to unravel relevant features of this group of strains as well 
evaluate clonal relationships;  
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3. Methods  
3.1. Samples and data collection 
Between October 2015 and June 2017, the National Reference Laboratory for Gastrointestinal 
infections (NRL_GI) from the Portuguese National Institute of Health Dr. Ricardo Jorge (INSARJ) 
received, under the scope of CDI surveillance, stool samples from patients with suspected CDI from 11 
Portuguese hospital centres. The samples had positive enzyme immunoassay (EIA) test for the presence 
of toxin A/toxin B and/or positive EIA for GDH. Each sample was accompanied by a short questionnaire 
on the patient’s clinical and epidemiological data, including age, sex, place (hospital or community) and 
time of symptoms onset. CDI cases were classified as healthcare facility–onset healthcare 
facility-associated (HO-HCFA) when the symptoms onset occurred > 48 h after admission to a 
health-care facility, community-associated (CA) when the onset of symptoms occurred outside a 
health-care facility or less than 48 h before admission, and unknown when no data was available (Cohen 
et al., 2010). A total of 455 samples were studied. 
3.2. Clostridium difficile culture  
Faecal samples were subject to alcohol shock treatment:  1 g of stool was mixed with 1 mL of 
ethanol 100%; for liquid stools, 1 mL was mixed with 1 mL of ethanol, and left to rest for 60 min at 
room temperature. Then, 1-2 drops of the faeces/ethanol suspension were inoculated on a selective 
chromogenic medium chromID™ C. difficile agar (CDIF) (bioMérieux) for the growth of C. difficile. 
The CDIF plates were examined after incubation at 37 °C for 48 h, under anaerobic atmosphere 
generated by AnoxomatTM (MART Microbiology BV) with a catalyst.  
Suspected C. difficile colonies were selected based on colour and morphology (5-7 mm in 
diameter, flat with a filamentous edge); for each isolate one colony was cultured onto a Brain Heart 
Infusion (BHI) agar plate and its identity confirmed by PCR targeting the glutamate dehydrogenase gene 
(gluD gene). 
3.3. Antimicrobial susceptibility test 
Antimicrobial susceptibility testing was performed for the antibiotics moxifloxacin (5 g), 
vancomycin (5 g), metronidazole (5 g) and rifampicin (5 g) by disk diffusion (Oxoid). For a 
subgroup of strains, the minimum inhibitory concentration (MIC) of imipenem, chloramphenicol, 
tetracycline, tigecycline, clindamycin and erythromycin were determined by diffusion gradient, using 
Etest® strips (bioMérieux) according to the manufacturer’s instructions. Briefly, one colony from each 
cultured sample was selected and subcultured on BHI plates and incubated anaerobically at 37 °C for 
24 h. Overnight cultures of C. difficile strains were suspended in Schaedler Broth with Vitamin K1 (BD, 
BBL™) to a density equivalent to 1.0 McFarland (~3x108 CFU/mL), and then a sterile cotton swab was 
used to spread the inoculum evenly onto the Brucella Agar (BA) supplemented with 5% Sheep Blood, 
Hemin and Vitamin K1 (BD, BBL™) plates. After the surface was completely dry, antibiotic disks or 
Etest® strips were applied to each plate. The plates were incubated anaerobically at 37 °C for 24 h for 
the ones containing the disks and the imipenem Etest® strips, and for 48 h for the remaining plates 
containing Etest® strips. For antibiotic disks, the following zone diameter ecological cut-off proposed 
by Erikstrup et al. (2012) was used: ≥ 20 mm, ≥ 23 mm and ≥ 19 mm, to moxifloxacin, vancomycin, 
metronidazole respectively. For rifampicin, and in order to make the transition to disk diffusion, a 
comparative test was performed using both antibiotic disks (5 g) and Etest® strips, and strains were 
categorized as susceptible if inhibition zone diameter was ≥ 30 mm, corresponding to MIC < 0.004 
mg/L, according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
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guidelines (2017, http://www.eucast.org/clinical_breakpoints/);  resistant  strains  all had  inhibition 
zone  diameter ≤ 6 mm, corresponding to MIC > 32 mg/L. 
MICs breakpoints were defined according to Freeman et al. (2015) for: imipenem (≥ 16 mg/L), 
chloramphenicol (≥ 32 mg/L), tigecycline (> 0.25 mg/L) and for clindamycin (≥ 8 mg/L), and according 
to Clinical and Laboratory Standards Institute (CLSI) breakpoint guideline (M11-A7, 2012) for 
tetracycline (≥ 16 mg/L) and erythromycin (≥ 8 mg/L). To optimize growth of C. difficile, all necessary 
medium were reduced for 18–24 h in an anaerobic atmosphere before use (CLSI, 2012). The preparation 
of inoculum, inoculation and incubation was accomplished within 30 min in order to avoid prolonged 
exposure to aerobic atmosphere. 
3.4. Molecular characterization of strains 
DNA was extracted from a 24 h culture using the NucliSENS® easyMAG® (bioMérieux) 
automated system (bioMérieux) according to the manufacturer’s instructions. In brief, samples were 
placed in the sample vessel and were followed by lysis incubation. Magnetic silica was added to the 
samples followed by automatic extraction with the Generic 2.0.1 protocol.   
The primers used in this study, their respective sequences, targets and references are presented 
in Table 3.1. The primers’ final concentrations used in the PCR mixtures, the expected PCR product 
length, annealing temperature and gel electrophoresis conditions are all described in Table 3.2. 
3.4.1. Identification, toxin profiling and ribotyping 
The extracted DNA was used for amplification of tcdA, tcdB, cdtA, cdtB, toxin-encoding genes 
as well as of for the gluD gene of C. difficile in a single multiplex PCR by using the respective primers 
listed in Table 3.1. In order to investigate deletions in tcdA gene repeating regions, an additional PCR 
was performed, using the primer pair NKV011/NK9, resulting in a 2535 bp amplicon when no deletion 
is present, and 1700-1800 bp amplicon when deletions are present. 
Multiplex PCR was carried out using HotStarTaq Master Mix (Qiagen) while PCR targeting 
only the tcdA gene was carried out using RANGER DNA Polymerase (Bioline). 
PCR ribotyping of isolates was determined using the primer set described by Bidet, Frédéric, 
Valérie and Petit (1999) and a capillary gel electrophoresis-based approach as described by Indra et al. 
(2008). The reaction was performed using KAPA2G Robust HotStart DNA Polymerase (Kapa 
Biosystems) and employed a 16S rRNA primer labelled at the 5’ end with 6-carboxyfluorescein 
(6-FAM). The PCR RTs were determined by uploading the data to the online database Webribo 
(https://webribo.ages.at/). 
3.4.2. Detection of genes and point mutations associated with antibiotic resistance 
The primer pairs E5-E6, CL1-CL2 and TETMd/TETMr were used to identify the presence of 
ermB, catD and tetM gene, respectively. For identification of transposons carrying the tetM, the int and 
the tndX genes were used as markers of Tn916 and Tn5397 elements, respectively, according to 
Spigaglia et al. (2005). 
BioTaq DNA polymerase (Bioline) was used for screening of these genes and transposons 
carrying the tetM. 
Point mutations associated with resistance to rifampicin and moxifloxacin were screened on 
rpoB and on gyrA/gyrB genes, respectively (Curry et al., 2009; Dridi, Tankovic, Burghoffer, Barbut, &  
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Table 3.1. Primers used in this study and their respective sequences, targets and references. 





Olsen (2008)  
tcdA-R3969 AGTTCCTCCTGCTCCATCAAATG 
tcdB-F5670 CCAAARTGGAGTGTTACAAACAGGTG 







ctdB-F617 TTGACCCAAAGTTGATGTCTGATTG cdtB 




al. (2007)  Cdiff_GluDR1 TTCCTAATTTAGCAGCAGCTTC 
NKV011 TTTTGATCCTATAGAATCTAACTTAGTAAC 
tcdA 
Kato et al. 
(1999) NK9 CCACCAGCTGCAGCCATA 
16S 6 FAM-GTGCGGCTGGATCACCTCCT 16S-23S 
rRNA 
Bidet et al. 
 (1999) 23S CCCTGCACCCTTAATAACTTGACC 
E5 CTCAAAACTTTTTAACGAGTG 





















Curry et al., 
(2009) CDrpoB2-R ACAGCACCATTTACAGTTCTA 
gyrA1 AATGAGTGTTATAGCTGGACG 
gyrA 

























G8Cd-F 6 FAM-TGTATGAAGCAAGCTTTTTATT G8Cd 
G8Cd-R AATCTAATAATCCAGTAATTTAAATT G8Cd 
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Petit, 2002). 
Fragments of those genes were amplified with BIO-X-ACT Short DNA Polymerase (Bioline) 
followed by Sanger sequencing using the forward primers, CDrpoB2-F, gyrA1 and gyrB1, respectively. 
Before sequencing, all PCR products were treated with ExoSAP-IT (USB Corporation) according to the 
manufacturer’s instructions. Capillary sequencing was performed with a BigDye terminator Reaction in 
an ABI 3130xl Genetic Analyzer (Applied Biosystems). 
 
Table 3.2. Primer pairs used in this study, final concentration used in PCR mixture, PCR 
annealing temperature, amplicon size and electrophoresis conditions.  
3.4.3. Multilocus variable number tandem repeat analysis 
Six variable-number tandem-repeat (VNTR) loci amplification (A6Cd, B7Cd, C6Cd, E7Cd, 
G8Cd and CDR60) were carried out for all RT017 and RT265 isolates using the primer set listed in 
Table 3.1, developed by van den Berg, Schaap, Templeton, Klaassen and Kuijper (2007) and Tanner, 
Hardy and Hawkey (2010) for multilocus variable number tandem repeat analysis (MLVA). Briefly, 
each forward primer was fluorescently labelled at 5’ end with either 6-carboxyfluorescein (6-FAM), 
hexachlorofluorescein (HEX) or 4',5'-dichloro-2',7'-dimethoxyfluorescein (JOE) (Table 3.1). PCR 
amplifications were performed using KAPA2G Robust HotStart DNA Polymerase (Kapa Biosystems). 
The repeat numbers for each locus were determined by capillary electrophoresis using an ABI 3130xl 
Genetic Analyzer (Applied Biosystems) and the results used to generate a dissimilarity matrix based on 
the Manhattan distance between isolates. The dissimilarity matrix was used to construct a minimum 
spanning tree using the summed absolute distance as coefficient in the BioNumerics (version 3.5) 











(agarose gel %; time; 
voltage) 
tcdA-F3345/ tcdA-R3969 0.67 
54 ºC 
629 












ctdB-F617/ cdtB-R878 0.11 262 
Cdiff_GluDF1/Cdiff_GluDR1 0.67 158 
NKV011/ NK9 0.625 58°C 2535/1700-1800a 1.5%; 40 min; 100 V 
16S/ 23S 0.25 54°C - - 
E5/ E6 0.75 50°C 711 1.5%; 30 min; 100 V 
CL1/CL2 0.75 50°C 500 1.5%; 30 min; 100 V 
TETMd/ TETMr 0.75 50°C 1080 1.5%; 30 min; 100 V 
INTf/ INTr 0.75 50°C 925 1.5%; 30 min; 100 V 
tndx1/ tndx3 0.75 50°C 1608 1.5%; 30 min; 100 V 
CDrpoB2-F/ CDrpoB2-R 0.5 52°C 485 1.5%; 30 min; 100 V 
gyrA1/ gyrA2 0.5 50°C 390 1.5%; 30 min; 100 V 
gyrB1/ gyrB2 0.5 50°C 390 1.5%; 30 min; 100 V 
VNTR primer pairs 0.22 51°C - - 
a Amplicon size if no tcdA deletion is present/if deletion is present.  
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software (Applied Maths, Sint-Martens-Latem, Belgium). The minimum spanning tree was built with 
VNTR information of RT017 strains from INSARJ database. 
For each locus, the summed tandem-repeat difference (STRD) were also calculated and MLVA 
types associated based on the smallest STRDs: isolates with STRD ≤ 10 were considered genetically 
related regardless the number of different loci; the clonal complexes were defined by a STRD ≤ 2 
between two isolates that were either single or double locus variants of each other. 
3.5. Whole Genome Sequencing  
Whole genome sequencing (WGS) was performed for eight RT017 strains and one RT265 strain 
for genomic comparison between the two groups. 
For each strain, DNA sample was extracted using the Isolate II Genomic DNA kit (Bioline, UK) 
according to the manufacturer’s protocol, and further quantified using a fluorometric method (Qubit 
dsDNA HS Assay Kit). For each isolate, paired-end (2 x 250 bp) WGS was carried out in a MiSeq 
equipment (Illumina Inc., CA, USA) available at INSARJ. FastQC version 0.11.5 was subsequently 
applied to check the reads’ quality before and after quality improvement measures carried out using 
Trimmomatic version 0.36. Then, high-quality processed reads were subjected to de novo genome 
assembly using SPAdes (version 3.10.1). Draft genome sequences were analysed in order to: i) perform 
genome annotation to identify functional properties and biological roles of genes using RAST server 
version 2.0 (http://rast.nmpdr.org/); ii) perform in silico Multilocus Sequence Typing (MLST) and allele 
determination of well-known virulence-associated genes, using the online platform available at 
PUBMLST (http://pubmlst.org/); iii) search for the presence of putative antimicrobial resistance (AMR) 
genes using both CARD (https://card.mcmaster.ca/) and ResFinder version 2.1 
(http://www.genomicepidemiology.org/) database; iv) identify potential dissimilarities enrolling AMR 
genes; and v) verify the genomic context of potential horizontally-transferable AMR genes. Open 
reading frames (ORFs) visualisation was conducted using SnapGene Viewer (version 4.0.5) software. 
Sequence reads (after quality improvement using Trimmomatic) of all C. difficile RT017 clinical 
isolates were mapped to the published genome of the RT017 reference strain, C. difficile M68 (GenBank 
accession number: NC_017175) using Snippy v3.1 tool (https://github.com/tseemann/snippy); base-pair 
calls at each position in the genome were used to identify single nucleotide polymorphisms (SNP) 
between the clinical isolates and the reference genome. MEGA5 software 
(http://www.megasoftware.net) was applied to calculate matrices of nucleotide distances. RAxML (NG 
v0.4, beta) was applied to perform maximum likelihood phylogenetic reconstructions over the obtained 
core-genome SNP alignment (enrolling 74 variant sites) by using the general time-reversible model 
(GTR+G) with bootstrapping (1000 replicates). Microreact platform (https://microreact.org/) was used 
to visualize the phylogenetic three linked to antimicrobial resistance data.  
3.6. Cloning and expression of ermG gene  
In order to verify if the presence of ermG gene by itself leads to MLSB resistance, a multicopy 
plasmid carrying the gene was inserted in C. difficile 630∆erm, and antimicrobial susceptibility of the 
transformed strains were evaluated. 
To express the ermG gene under the control of a Ptet inducible promoter, the ermG gene with 
its ribosome-binding site (positions -12 to +793 from the translational start codon) was amplified using 
primers ermG850D (GGATTCGGAGAGGTTATAATGAACAAAG) and ermG1660R 
(ATAGTTTAGCGGCCGCATTTTAACTTATGCTACCCTACC). The resulting PCR product (810 
bp) was digested with EcoRI and NotI and cloned into pAM25, a derivative of pRPF185 lacking the 
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gusA gene (Fagan & Fairweather, 2011). Using the Escherichia coli HB101 (RP4) strain containing 
either pRPF185 or pMS534 (pAM25-ermG), these plasmids were transferred by conjugation into C. 
difficile 630∆erm. 
Transformable strains were incubated at 37°C for 24 h in BHI plates with 15 µg/mL of 
thiamphenicol. Overnight cultures were suspended in Schaedler Broth with Vitamin K1 (BD, BBL™), 
to a density of 1.0 McFarland and mixture with 250 ng/mL of anhydrotetracycline and 15 µg/mL of 
thiamphenicol; 500 µL of the mixture were scattered onto BA plates, and the excess suspension was 
aspirated with a sterile disposable Pasteur pipette. MIC determination of erythromycin and clindamycin 
was performed using Etest® strips (bioMérieux). A C. difficile 630∆erm strain carrying the multicopy 
plasmid, but without the ermG insertion was used as control. 
The Sanger sequencing, capillary electrophoresis and WGS were performed at the Unidade de 
Tecnologia e Inovação, of the Departamento de Genética Humana. 
The construction of ermG inducible strains was carried at the Microbial Development Lab, 
Instituto de Tecnologia Química e Biológica - António Xavier, Universidade Nova de Lisboa, Portugal. 
  




4.1. Toxin profile and ribotyping of Clostridium difficile clinical strains 
Of the 455 samples sent to the Reference Laboratory of INSARJ, a total of 378 C. difficile strains 
were recovered after anaerobic culture and identification by PCR targeting gluD.  
Overall, 345 isolates (91.3%) were toxigenic and 33 (8.7%) were non-toxigenic strains. Among 
the 325 strains with the genotype tcdA+/ tcdB+, 89 harboured also the CDT-encoding genes (cdtA+/ 
cdtB+).  Specific PCR for toxin A revel that some of the strains characterized as tcdA+ by the multiplex 
had a large deletion in the gene, thereby, 20 isolates were identified as tcdA-/tcdB+, none of them were 
positive for cdtA/cdtB (Table 4.1). 
 
Table 4.1. Toxin gene contents of 345 toxigenic Clostridium difficile clinical isolates. 
Concerning RTs, lack of amplification was observed for two isolates; in the remaining 376 
isolates, a high diversity was observed (Figure 4.1).  
 
 
Figure 4.1. Distribution of PCR-ribotypes among 376 Clostridium difficile clinical strains isolated from eleven 
Portuguese hospital centres during 2015-2017. “Others” includes 66 RTs with less than 10 isolates each. The number of 
strains are represented on top of the bars. 
 
RT027 was the most prevalent (13.8%), followed by RT014 (8.2%) and RT106 (6.1%). The 
percentage of RT017 was 5.1%, being the fourth most representative RT, followed by RT078 and RT002 
(4.5%), RT126 (4.3%), RT020 (3.7%) and RT005 (2.9%). Sixty-six less common RTs accounted for 
46.8% of the total were found, adding a total of 75 different RTs among 376 isolates.  
Three of the most frequent RTs were positive for tcdA, tcdB and also cdtA/cdtB (RT027, RT078 
and RT126), while the 19 strains from RT017 were tcdA-/tcdB+, as well a single strain from RT265. 
Toxin gene, isolates No. (%)  CDT Isolate no. (%) 
tcdA+/ tcdB+, 325 (94.2) 
+ 89 (25.8) 
- 236 (68.4) 
tcdA-/tcdB+, 20 (5.8) - 20 (5.8) 
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The distribution of the RTs varied widely between and within hospitals. However, 11 of the 19 
isolates from RT017 were detected in 11 patients hospitalized in the same ward of the same hospital 
(herein designated as Hospital A), with the following temporal distribution: 1 patient in January, 6 
patients in February, 1 in March, 1 in April, 1 in June and 1 in July, all in 2016, suggesting the occurrence 
of nosocomial transmission.  
4.2. Patients characteristics and clinical data  
The 378 C. difficile strains were isolated from 374 different patients, as four patients were 
colonized by two different strains (two different RTs). Table 4.2 summarize the relevant demographic 
and clinical data of the patients.  
The ratio female:male was 1.3 and the majority of CDI cases (70.1%) was from older patients 
(age ≥ 65 years). 
Most cases corresponded to hospital-acquired CDI (63.1%) but there were 90 cases associated 
with the community setting (24.1%) and 48 cases (12.8%) classified as unknown due to lack of 
information.  
 
Table 4.2. Demographic and clinical data of patients with positive culture for Clostridium 
difficile. 
Patients characteristics no. (%) 
Gender (n = 371) Males 158 (42.6) 
Age (n = 264) 
Mean age in years  69 
< 18 15 (5.7) 
18 - 65 years  64 (24.2) 
≥ 65 years  185 (70.1) 
CDI classification (n = 374) 
HO-HCFA 236 (63.1) 
CA 90 (24.1) 
Unknown 48 (12.8) 
Antibiotics exposure within three months 
before CDI diagnosis (n = 374) 
Yes 111 (29.7) 
No 30 (8) 
Unknown 233 (66.3) 
HO-HCFA, healthcare facility–onset health-care facility-associated;  
CA, community associated. 
 
Regarding previous antibiotherapy, at least 29.7% of the patients received antibiotics within 
three months before CDI diagnosis, being that 8% had not been exposed to this risk factor. However 
most of the patients (66.3%) had no data available.  
4.3. Antimicrobial susceptibility 
The antimicrobial susceptibility for moxifloxacin, vancomycin, metronidazole and rifampicin 
was investigated for 183 toxigenic strains (Table 4.3).  
Overall, 30.1% (55/183) were moxifloxacin-resistant. All the strains from the frequently 
detected RT027 and RT017 were resistant to moxifloxacin, while for others an important frequency was 
observed, such as 89% (8/9) for RT126, 50% (6/12) for RT078.  
Focus on toxin A-negative/toxin B-positive strains isolated in Portugal 
17 
 
All tested strains were susceptible to vancomycin. When analysing the results for metronidazole 
it was noticed that only 4 strains were resistant, 3 belonged to RT027 and one to RT651. However, these 
results need to be confirmed by Etest® strips and/or agar dilution to determine the exact MIC, since the 
inhibition zone for these isolates was close to the breakpoint cut-off established.  
Rifampicin resistance was observed in 21 strains (inhibition diameter = 6 mm), of which 19 
belonged to RT017, one to RT043 and one to RT241.  
 
Table 4.3. Antimicrobial susceptibility of Clostridium difficile clinical strains, determined by  
disk diffusion. 
 
Imipenem susceptibility test was performed for 181 strains belonging to 57 different RTs. Only 
RT017 strains exhibited a resistant phenotype to this antibiotic after 24 h of incubation, with a MIC 
range between 32 to > 32 mg/L. The strain from RT265, also tcdA-/tcdB+ was susceptible to imipenem 
(MIC= 2 mg/L). 
Since RT017 has been described as multiresistant, the susceptibility profile for other antibiotics 
by Etest® was analysed (Table 4.4). All RT017 strains presented high levels of resistance to clindamycin 
and erythromycin, and were also resistant to tetracycline. On the other hand, strains were highly 
susceptible to chloramphenicol and tigecycline, with very low MICs. 
 
Table 4.4. Antimicrobial susceptibility of 19 Clostridium difficile RT017 strains 
determined by E-test®. 
 
Antimicrobial agents  
Resistant, 
no. (%) 
Resistance according to RT (no, %) 
Moxifloxacin (n = 183) 55 (30.1) 
RT027 (18, 100%); RT017 (19, 100%); RT126 (8, 
89%); RT078 (6, 50%); RT106 (1, 1.7%); RT241 (1, 
50%); RT449 (1, 50%); RTAI-84 (1, 50%) 
Vancomycin (n = 183) 0 NA 
Metronidazole (n = 183) 4 (2.2) RT027(3, 17%); RT651 (1,14%) 
Rifampicin (n = 183) 21 (11.5) RT017 (19, 100%); RT043 (1, 50%); RT241 (1, 50%) 
NA, not applicable. 
 
Antimicrobial agents 




Chloramphenicol  3 - 6 0 
Tetracycline   16 – 24 19 (100%) 
Tigecycline  0.023 – 0.047 0 
Clindamycin > 256 19 (100%) 
Erythromycin  > 256 19 (100%) 
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4.4. Determinants of antimicrobial resistance 
In order to complement the antimicrobial susceptibility data, PCR targeting several determinants 
of resistance was performed in 338 strains, 308 toxigenic and 30 non-toxigenic. The results for ermB, 
tetM, transposons and catD are summarized in Table 4.5. The ermB gene, conferring resistance to MSLB 
antibiotics, was detected in 34 strains (10.1%), while tetM, conferring resistance to tetracycline, was 
identified in 68 strains (20.12%), of which 62 were associated with Tn916-like element (int-positive), 4 
with a Tn5397 element (tndX-positive) and other 4 presented a negative result for both 
transposons-markers.  
Twenty-two strains (6.5%) contained both ermB and tetM genes and belonged mostly to three 
toxigenic RTs, RT017, RT126 and RT012, and to one non-toxigenic type, RT039.  
Overall, among the 30 non-toxigenic strains tested, 13 (40%) were positive for at least one 
resistance determinant. 
 
Table 4.5. Distribution of antibiotic resistance determinants according to PCR-ribotype. 
All strains were negative for catD, which confers resistance to chloramphenicol, and 258 
(76.3%) did not carry any of the resistance determinants studied. 
The rifampicin-resistant strains were analysed for presence of mutations at rpoB gene, using C. 
difficile 630 (CD630_00660) as control. All of the identified amino acid substitutions were located 
between amino acid 502 and 507 of RpoB. RT017 strains contained both the substitutions His502Asn 
and Arg505Lys, which were also found in a RT241 resistant-strain. A novel amino acid substitution 
(Ser507Leu), near the region of mutations associated to rifampicin-resistance, was found in a resistant 
strain from RT043, which didn’t harbour any of the know mutations. 
Overall, one substitution in GyrA (Thr82Ile) and one substitution in GyrB (Ser416Ala) were 
identified in the moxifloxacin-resistant strains analysed. The well-known mutation Thr82Ile was detect 
in different RTs and was present in of the majority of the moxifloxacin-resistant isolates, including in 
all RT017 strains, while no mutations were found in GyrB for this RT. RT078 an RT126 
No. of strains 
(n = 338) 
ermB tetM int tndX catD RTa (no.) 
258 - - - - - 
RT027 (40); RT014/0 (27); RT002 (16); 
RT020 (13); RT005 (7) 
12 + - - - - 
RT651 (2); RT012(2); RT009b (1); RT010b (1); 
RT031b (1); RT039b (1); RT106 (1); RT241 (1); 
RT416 (1); RTAI-83 (1) 
42 
- + 
+ - - 
RT017 (11); RT078 (15); RT126 (9); RT002 (1); 
RT005 (1); RT039b (2); RT043 (2); RT645 (1) 
2 - + - RT012 (1); RT039b (1) 
2 - - - RT027 (1); RTAI-9-1 (1) 
18 
+ + 
+ - - 
RT017 (8); RT005 (1); RT039b (3); RT067b (1); 
RT078 (1); RT106 (1); RT126 (3) 
2 - + - RT039b (2) 
2 - - - RT012 (2) 
a Mostly representative ribotypes; 
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moxifloxacin-resistance strains harbour the two mutations, one in GyrA and one in GyrB, although the 
mutation GyrB (Ser416Ala) seems to not be related to fluoroquinolone resistance, since it has been 
previously detect in susceptible strains (Spigaglia et al., 2008).  
The results of mutations analyses are resumed in Table 4.6. 
 
Table 4.6. Distribution of predicted amino acid substitutions in RpoB, GyrA and GyrB associated 
with antibiotic resistance according to PCR-ribotypes. 
Considering the antimicrobial phenotypes and genotypes, the strains from RT017 (tcdA-/tcdB+) 
were the most resistant, presenting simultaneous resistance to several antibiotics representative of six 
different classes: moxifloxacin (fluoroquinolones), imipenem (carbapenems’), erythromycin 
(macrolides), tetracycline (tetracyclines), clindamycin (lincosamides) and rifampicin. 
For this group of 19 RT017 strains, there was a good correlation between phenotype and 
genotype for moxifloxacin (gyrA mutations), rifampicin (rpoB mutations) and tetracycline (presence of 
tetM). Concerning clindamycin and erythromycin, belonging to the MSLB group, only eight of the 19 
strains were ermB positive.  
Considering that RT017 was one of the most frequently detected RT, was multi-resistant and 
likely harbours new resistance determinants, few of these isolates were further studied by MLVA and 
WGS, in order to identify clonal groups and particular genomic features. Since these strains have a 
particular toxin genotype (tcdA-/tcdB+), the only strain from RT256 sharing this genotype was also 
included in the analysis. 
4.5.  Study of toxin A-negative/toxin B-positive strains (RT017 and RT265)  
The 20 strains with the profile tcdA-/tcdB+ have only been found in two among the 11 hospital 
centres: 11 cases from RT017 were detected in a limited period in 2016 (January-July) in hospital A, 1 
case from RT265 was isolated in a sample from November 2015, in hospital A, and the remaining 8 
were isolated from another hospital (here designated as hospital B), during the study period.  
4.5.1. Phylogenetic analysis by multilocus variable number tandem repeat analysis  
MLVA was performed for 16 of these strains (15 RT017 and 1 RT265) and compared to the 
profile of 34 previously isolated strains from RT017, and resulted in 32 unique types (Figure 4.2). 
Supplementary table 1 contains the MLVA profiles for all the strains. 
Concerning RT017 strains, MLVA analysis showed that VNTR loci C6 and G8 were the most 
variable  (15-29 and 31-40 repeats, respectively), while  the  number  of  repeats  in loci  A6 and E7 was  
RpoB GyrA GyrB RT (no.) 
His502Asn and Arg505Lys Thr82Ile none RT017 (19); RT241 (1) 
Ser507Leu NA NA RT043 (1) 
NA Thr82Ile none 
RT027 (18); RT106 (1); 
RT449 (1); RTAI-84 (1) 
NA Thr82Ile Ser416Ala RT078 (6); RT126 (8) 
New mutation highlighted in bold face; 
NA, not applicable. 
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Figure 4.2 Minimum spanning tree of multilocus variable number tandem repeat analysis data for one Clostridium difficile RT265 and 49 RT017 isolates. Each circle represents either one 
unique isolate or more isolates that have identical MLVA types, inside the circles are specified the hospital where the patient was located and the isolates number. The numbers between the circles 
represent the summed tandem-repeat difference (STRD) between MLVA types. Solid lines represent single locus variants, dotted line represent double locus variants, dashed line represent 3-locus 
variants and interrupted lines represent 4-locus variants between MLVA types. Clonal clusters (CC) are defined by an STRD of ≤ 2, and genetically related clusters are defined by an STRD of 
≤10. The isolates are marked in different colors according to the year in which it was isolated as shown in the key (on the right side of the figure). The tree has been redrawn for ease of viewing 
and is not to scale. 
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constant or only slightly different (2 and 7-8 repeats, respectively). All the R0T17 strains were 
genetically related (STDR ≤ 10), comprising 5 clonal clusters (CC).  
Isolates from hospital B were collected during six-years (2012-2017), and the respective MLVA 
types were dispersed by different CC without any link between cluster/year. The largest complex (CC-2) 
consisted of 21 isolates from hospital B (1 isolate from this study and 20 previous isolates) that were 
collected during five different years, reflecting the genetic proximity of the isolates, which is consistent 
with a persistent clone in that hospital setting.  
All 11 RT017 isolates from hospital A generated MLVA types that presented single locus 
variation among each other, with an STRD of ≤ 10, indicating that they are highly related to each other, 
which is consistent with nosocomial transmission. Six of these isolates belong to CC-3, which also 
includes one isolate from hospital B that was isolated in 2013.  
The only isolate from RT265 showed a STRD of 53 from one MLVA type of hospital B isolated 
in 2016 and belonging to CC-1, with variation in four loci, and therefore it is not genetically related to 
the RT017 isolates.  
4.5.1. Whole genome sequencing analysis  
WGS was performed for three isolates from hospital A (one from each of the months January, 
February and July 2016), 5 RT017 strains from hospital B (from August, October and December 2016 
and February 2017) and one RT265 strains from hospital A. In addition, WGS data from 25 previously 
sequenced isolates from RT017 was included in the analysis, 22 from hospital B and three from a third 
hospital (here designated as hospital C).  
In silico MLST analysis of RT017 indicated that all strains belonged to sequence type 37 (MLST 
clade 4); RT265 assigned as sequence type 88 (MLST clade 4). WGS analysis confirmed the presence 
of a complete tcdB (PubMLST allele 9), the absent of genes coding for CDT and a large deletion in 
tcdA.  
A phylogenetic tree was generated based on the core-genome single nucleotide polymorphisms 
(SNPs) analyses of the RT017 strains, revealing two main groups, one containing the imipenem-resistant 
strains from hospitals A and B and other single cluster containing three susceptible strains from hospital 
C (Figure 4.3 A). SNPs analysis showed that all the isolates from hospital A were almost 
undistinguishable from each other (1 SNPs variant), consistent with nosocomial transmission, while 
isolates from hospital B were more diverse as they were obtained over several years. Notably, one isolate 
from 2017 had only 4 SNPs distance from one isolate from 2012, confirming the persistence of the same 
clones over the years in that hospital. Overall, a similar separation of the isolates by the two analyses 
can be observed as they apparently distribute themselves in the branches of the SNP-based maximum 
likelihood phylogenetic tree in the same way that they are distributed in the branches of the MLVA 
minimum spanning tree. This agreement was firstly observed as the strains of each hospital grouped 
together but were separated from the other hospitals, being this separation more evident for the SNPs 
analysis. 
All strains revealed a large genome sequence identity, marked by only 74 SNPs when compared 
to mapping against the C. difficile M68 genome (GenBank accession number: NC_017175). 
Twenty-two of these variant sites discriminate the isolates from this work belonging to hospital A and 
B, from the previous isolates, from hospitals B and C. Two of these SNPs corresponded to synonymous 
substitutions, but a considerable number (20) originated, non-synonymous substitutions (Table 4.7). 
These  include  genes  encoding  proteins involved  in  DNA transcription,  cell structure and regulation, 






















Figure 4.3. Phylogeny of Clostridium difficile RT017 clinical isolates and genetic determinants of antibiotic resistance based on WGS sequences. (A) core-genome SNP-based maximum 
likelihood phylogeny of 33 RT017 C. difficile clinical strains generated by mapping reads against to the reference genome C. difficile M68. The isolates are marked in different colors according 
to the work as shown in the key (on the right side of the figure). (B) Heatmap visualizing the distribution of antimicrobial resistance determinants together with its associated phenotypes for each 
isolate (see color key on the right side of the figure). Mutations refer to nucleotide change when compared resistant and susceptible strains; no mutations refer to the absence of nucleotide variations 
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Table 4.7. Unique single nucleotide polymorphisms only found at RT017 strains from this work from RT017 strains previously isolated.  





Product/putative function Biological Process † 
53164 CDM68_RS00405 G605A Arg202Lys 
23S rRNA (guanosine(2251)-2'-O)-methyltransferase 
RlmB 
rRNA methylation 
67225 CDM68_RS00470 C2439T Asp813Asp DNA-directed RNA polymerase subunit beta' Transcription 
662258 CDM68_RS03290 G266A Gly89Asp DNA-binding response regulator Signal transduction system    
902504 CDM68_RS04270 G251T Gly84Val TetR family transcriptional regulator AMR, regulation of transcription 
935302 CDM68_RS04430 A820G Ile274Val MFS transporter Transmembrane transport 
943701 CDM68_RS04460 A339T Ala113Ala ABC transporter ATP-binding protein AMR, transport 
1053823 CDM68_RS04965 A281T Lys94Ile hypothetical protein HP 
1392809 CDM68_RS06540 C560T Ala187Val translation initiation factor IF-2 Protein biosynthesis 
1393468 CDM68_RS06540 G1219A Ala407Thr translation initiation factor IF-2 Protein biosynthesis 
1553788 CDM68_RS07280 C134T Thr45Ile dihydropteroate synthase Folate biosynthesis 
1666351 CDM68_RS07765 G214T Gly72* hypothetical protein HP 
1671129 CDM68_RS07795 T209C Ile70Thr imidazoleglycerol-phosphate dehydratase Amino-acid biosynthesis 
2010723 CDM68_RS09450 C595A Pro199Thr Cell wall-binding repeat-containing protein Cell structural 
2251300 CDM68_RS10605 C407A Ala136Glu Lactate utilization protein Lactate metabolic process 
2662461 CDM68_RS12420 G253A Gly85Ser amidohydrolase Proteolysis 
3122003 CDM68_RS14375 G1609T Asp537Tyr preprotein translocase subunit SecA Protein transport 
3541711 CDM68_RS16075 G700A Glu234Lys SAM-dependent DNA methyltransferase DNA methylation 
3641231 CDM68_RS16560 A398G Asp133Gly hypothetical protein HP 
3643271 CDM68_RS16570 C775T Pro259Ser two-component sensor histidine kinase Signal transduction system   
3795253 CDM68_RS17445 C30A Cys10* HxlR family transcriptional regulator Transcription 
4026545 CDM68_RS18530 C220T Gln74* SAM-dependent methyltransferase DNA methylation 
4045861 CDM68_RS18610 C578T Ala193Val hypothetical protein HP 
a Genome position relative to the annotation of the C. difficile M68 genome (accession number NC_017175); 
b The nucleotide changes are presented in the 5’ to 3’ direction and is relative the reference C. difficile M68 genome; 
† according to http://www.ebi.ac.uk/interpro 
Nonsense mutations leading to putative protein truncation are represented by an asterisk (*); 
AMR, antimicrobial resistance; HP, hypothetical protein. 
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response to environmental changes and metabolic reactions. It also includes hypothetical proteins and 
possible genes implicated in antimicrobial resistance as well. Nonsense mutations resulting in premature 
truncation of the encoding protein was observed in genes encoding for a S-adenosyl-methionine 
(SAM)-dependent methyltransferase, for a transcriptional regulator (HxlR family transcriptional 
regulator) and for a hypothetical protein.   
C. difficile usually contains four HMW PBP, except the strains from RT017, which contain a 
fifth pbp gene, here designated as pbp5 (corresponding to CDM68_RS02615 locus tag in C. difficile 
M68 strain). This gene was also found in the RT265 strain, in the same genomic context as the RT017 
strains, with both PBP5 sharing 99% homology. 
All the imipenem-resistant strains, from hospitals A and B, harboured mutations in HMW PBP 
genes, located near conserved motifs, when compared to imipenem-susceptible strains, but notably with 
different profiles: the resistant strains from hospital B have the two mutations previously reported (Isidro 
et al. 2017), one (G1663A) in pbp1  (corresponding to CDM68_RS04280 locus) leading to an amino  
acid  substitution  Ala555Thr,  and  the other (A2162C) in  pbp3 (corresponding to CDM68_RS05670  
locus)  resulting  in  the  amino acid substitution  Tyr721Ser;  isolates from hospital A harbour only the  
mutation (A2162C) in pbp3 (Figure 4.3 B). For this clone, no mutations were found in other PBPs 
encoding genes (pbp1, pbp2, pbp4 and pbp5). 
In silico screening of antimicrobial resistance genes based on WGS analysis using CARD and 
ResFinder databases, revealed the presence of several genes in this category. First, a gene encoding a 
putative chloramphenicol acetyltransferase CAT (CDM68_RS02605) was found in all the strains, 
although they were susceptible (Figure 4.3 B). 
The isolates from hospital B were positive for ermB gene, previously associated with resistance 
to MLSB antibiotics in C. difficile, confirming the results of the PCR screening, while all strains from 
RT017 from hospital A were positive for ermG gene. Both genes encode a rRNA adenine 
N-6-methyltransferase. Homology search of ermG using nucleotide Blast showed that this gene shared 
100% identity to ermG gene found in several other Gram-positive species, such as Enterococcus 
cecorum (RA45_RS03490 locus) and Lysinibacillus sphaericus (A7J11_00653 locus). Transformation 
of C. difficile strain 630∆erm with a plasmid containing ermG resulted in a resistance phenotype for 
clindamycin and erythromycin, with MIC > 256 mg/L, showing that this gene is functional in C. difficile 
and is associated with high level of resistance to both these antibiotics. 
The ermG gene was located inside a large region of 63.4 kb that displays traces of horizontal 
gene transfer (encompassing recombinases, phage-related proteins and flanked by transposases), as 
shown in Figure 4.4. Nucleotide Blast was conduct for the entire region, showing high degree of 
homology with an identical region present in a C. difficile non-toxigenic strain (Peptoclostridium 
difficile strain Z31, GenBank accession number: CP013196.1). Table 4.8 lists the suggested annotation 
and homologues locus tag (PubMed) for all the ORFs found at this putative mobile element containing 
the ermG gene. A streptogramin A acetyltransferase was also detected in this putative mobile element.  
Screening for resistance determinants at ResFinder also showed homology to other two genes 
possible involved in MLSB resistance, the mefA and the msrD genes, located near the ermG on the 
putative mobile element (Figure 4.4); blast of the nucleotide sequence gave 96% for a mefA gene 
(A6J31_02365) and 98% of identity for msrD (A6J31_02370) in Streptococcus sp. Those genes encode 
for a macrolide efflux MFS transporter Mef(A) and a ABC-F type ribosomal protection protein Msr(D), 
respectively (Table 4.8). 
Regarding the other classes of antibiotics, WGS analysis confirmed the results of the PCR 
screening.  









Figure 4.4. Genetic organization of the putative transposon in Clostridium difficile. Schematic representation of the 
putative mobile-element (63,400 bp) harboring the ermG gene in the genome of C. difficile MLSB-resistant strains; suggested 
gene annotation based on Nucleotide BLAST. Arrows indicate open reading frames (ORFs) and direction of transcription, size 
is proportional to gene length; ermG is shown in grey, with the remaining ORFs shown in black. 
 
For the isolate from RT265 no resistance determinant was found, in accordance to its antibiotic 
susceptibility profile. 
 
Table 4.8. Open reading frames and putative proteins that compose the mobile element carrying 
the ermG gene.  
ORF GenBank locus tag Product 
orf1 CDM68_RS02180 transposase 
orf2 CDM68_RS02185 RNA pseudouridine synthase 
orf3 CDM68_RS02190 23S rRNA (uracil(1939)-C(5))-methyltransferase  RlmD 
orf4 Thet_1692 methionine sulfoxide reductase A 
orf5 PCZ31_3874 Type-1 restriction enzyme R protein 
orf6 PCZ31_3873 hypothetical protein 
orf7 PCZ31_3872 hypothetical protein 
orf8 PCZ31_3871 EcoKI restriction-modification system protein HsdS 
orf9 PCZ31_3870 putative type I restriction enzymeP M protein 
orf10 PCZ31_3869 helix-turn-helix protein 
orf11 PCZ31_3868 hypothetical protein 
orf12 PCZ31_3867 hypothetical protein 
orf13 PCZ31_3866 hypothetical protein 
orf14 PCZ31_3865 hypothetical protein 
orf15 CDM120_RS02285 sigma-70 family RNA polymerase sigma factor 
orf16 PCZ31_3863 hypothetical protein 
orf17 Thet_1678 RNA biogenesis protein rrp5, putative 
orf18 PCZ31_3861 PD-(D/E)XK nuclease superfamily protein 
orf19 CDM120_RS02305 DUF2815 domain-containing protein 
orf20 PCZ31_3859 DNA polymerase I, thermostable 
orf21 PCZ31_3858 Phage antirepressor protein KilAC domain protein 
orf22 PCZ31_3857 hypothetical protein 
orf23 PCZ31_3856 Virulence-associated protein E 
orf24 PCZ31_3855 VRR-NUC domain protein 
orf25 PCZ31_3854 RNA polymerase-associated protein RapA 
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Table 4.8 continued page 2 of 2 
ORF GenBank locus tag Product 
orf26 CDM120_RS02340 phage-associated protein 
orf27 PCZ31_3852 HNH endonuclease 
orf28 PCZ31_3851 Phage terminase, small subunit 
orf29 PCZ31_3850 S-adenosylmethionine synthase 
orf30 PCZ31_3849 DNA adenine methyltransferase YhdJ 
orf31 PCZ31_3848 putative BsuMI modification methylase subunit 
orf32 PCZ31_3847 hypothetical protein 
orf33 PCZ31_3846 hypothetical protein 
orf34 CDM120_RS02375 amidoligase 
orf35 PCZ31_3844 AIG2-like family protein 
orf36 PCZ31_3843 hypothetical protein 
orf37 PCZ31_3842 Phage Terminase 
orf38 PCZ31_3841 Phage portal protein 
orf39 PCZ31_3840 TP-dependent Clp protease proteolytic subunit 
orf40 PCZ31_3839 Phage capsid family protein 
orf41 PCZ31_3838 hypothetical protein 
orf42 PCZ31_3837 Phage gp6-like head-tail connector protein 
orf43 PCZ31_3836 Phage head-tail joining protein 
orf44 PCZ31_3835 hypothetical protein 
orf45 PCZ31_3834 hypothetical protein 
orf46 CDM120_RS02440 phage major tail, phi13 family protein 
orf47 PCZ31_3832 hypothetical protein 
orf48 PCZ31_3831 hypothetical protein 
orf49 PCZ31_3830 Phage tail protein 
orf50 PCZ31_3829 Prophage endopeptidase tail 
orf51 PCZ31_3828 hypothetical protein 
orf52 PCZ31_3827 hypothetical protein 
orf53 PCZ31_3826 Glycosyl hydrolases family 18 
orf54 PCZ31_3825 Holin family protein 
orf55 PCZ31_3824 N-acetyl-anhydromuranmyl-L-alanine amidase 
orf56 PCZ31_3823 hypothetical protein 
orf57 PCZ31_3822 Transposon gamma-delta resolvase 
orf58 CM240_1374 recombinase 
orf59 PCZ31_3820 Transposon gamma-delta resolvase 
orf60 A6J31_02365 macrolide efflux MFS transporter Mef(A) 
orf61 A6J31_02370 ABC-F type ribosomal protection protein Msr(D) 
orf62 PCZ31_3817 
dephospho-CoA kinase/protein folding accessory  
domain-containing protein 
orf63 PCZ31_3816 Streptogramin A acetyltransferase 
orf64 RA45_RS03490 23S rRNA (adenine(2058)-N(6))-methyltransferase Erm(G) 
orf65 PCZ31_3814 IS66 Orf2 like protein 
orf66 PCZ31_3813 Transposase C of IS166 homeodomain protein 
Suggested annotation based on Nucleotide BLAST. 
Focus on toxin A-negative/toxin B-positive strains isolated in Portugal 
27 
5. Discussion 
Although CDI represents a great healthcare burden in developed countries, data in Portugal is 
still scarce with only a few reported studies. The present study provides an overview of the current state 
of C. difficile strains circulating in some hospitals in Portugal, concerning prevalent RTs and 
antimicrobial resistance rates and its associated resistance mechanisms, focusing on the tcdA-/tcdB+ 
and its molecular epidemiology. The results presented herein only reflects the distribution of strains in 
public hospitals that voluntarily agreed to contribute to the laboratory surveillance of CDI, and therefore 
it is not representative of the country overall.  
Of the 455 samples positive for C. difficile by EIA tests, 378 were recovered by culture, which 
is the golden standard method (Crobach et al., 2016). Therefore, the 77 samples with a negative culture 
may represent false positive diagnostics performed in the hospitals.  
The majority of the patients (70.1%) were 65 years or older, which is consistent with the criteria 
for disease severity defined by the ESCMID guidelines (Debast et al., 2014). A total of 5.7% were 
collected from children, suggesting that the epidemiology in the country is changing.  
It was not possible to gather detailed epidemiological data for all the patients included in the 
study. For example, it could not be determined the antibiotic prescription data for 66.3% of the 
individual patients, making difficult to interpret the meaning of this factor in the onset of CDI; or either 
information about previously patient’s hospitalizations to distinguish whether infections were 
community or hospital acquired due to recent hospital contact. As a result, some of the cases attributed 
as community-associated could have a hospital background that could change the analyses. Even so, 
most of the cases were defined as healthcare facility–onset, health-care facility-associated (63.1%) 
which is consistent with previously C. difficile epidemiology in the country (Santos et al., 2016).  
Concerning distribution of RTs, RT027 still remains the most frequently found, in agreement 
with a surveillance study conducted between 2010 and 2015 (Santos et al., 2016). RT027 was also 
reported as the most common RT in a European multicentre study of CDI in hospitalised patients with 
diarrhoea, including 19 countries, carried out between 2012 and 2013 (Davies et al., 2016), with variable 
frequencies between countries. In the present study, RT014 was the second most frequently as in the 
previous Portuguese study and also in agreement with the European study. Although here RT106 was 
the third most representative RT, it was not detected among the ten most commonly isolated RTs in the 
European multicentre study nor in the study performed before in Portugal before (Davies et al., 2016; 
Santos et al., 2016). This RT106 can be considered as an emergent RT in English hospitals, where it 
was found with high resistance rates to erythromycin and moxifloxacin (Brazier et al., 2008; Sundram 
et al., 2009); being also found in companion animals in different geographic locations (Álvarez-Pérez 
et al., 2017; Silva, Rupnik, Diniz, Vilela, & Lobato, 2015). Therefore, it is important to keep 
investigating the molecular epidemiology of the organism locally. 
The European multicentre study also established a relationship between RTs diversity and 
prevalence of RT027, where diversity decreased as the prevalence of RT027 increased (Davies et al., 
2016), suggesting that countries with a high frequency of RT027 strains would have an overall lower 
RT diversity. But this does not seem to be the current situation for Portugal, as in this study a great 
diversity of RTs were found (75 RTs including RT027), these results could be due to the collaboration 
of a higher number of hospitals, allowing a better view of the high variability in the country. 
Nevertheless, this RT diversity (namely within hospitals), also makes tempting to suggest that other 
transmission routes, in addition to contact between individuals in hospital-setting, are involved in the 
CDI cases. It should be noted that C. difficile epidemiology is also spreading to food animals on farms 
and companion animals that contact with an amount of people (Álvarez-Pérez et al., 2017; Knight et al., 
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2017; Thitaram et al., 2016), in river water and soil too (Janezic et al., 2012). C. difficile strains have 
also been shown to persist in the environment for a number of years (Cairns et al., 2015). Therefore, 
studies to investigate the RT prevalence in animals and the potential role of surface contamination in 
hospitals in the spread of C. difficile strains locally could be useful to understand this high variability.  
The pattern of antimicrobial resistance seems to differ among different RTs. Fluoroquinolone 
resistance has been reported worldwide; in a recent study from U.S. (Kociolek et al., 2016) a 
considerable proportion of moxifloxacin-resistant strains was found (36%), being related to the 
significantly higher proportion of RT027 strains among those patients. A pan-European longitudinal 
surveillance of antibiotic resistance among prevalent C. difficile RTs (Freeman et al., 2015) also reported 
variable rates of resistance between countries, overall 40% of the analysed strains were 
moxifloxacin-resistance, being mainly associated with specific and common RTs found in the study, 
such as RT356, RT018, RT027, and RT017. In the present work, resistance to moxifloxacin was 
observed in a frequency of 30.1% and was mainly associated with RT027 and RT017, which is not 
different from a previous study in Portugal (Santos et al., 2016). Those were also the most frequent RTs 
which may indicate a selective advantage for resistance to fluoroquinolone agents. 
Moxifloxacin-resistance was also found for other less frequent but highly virulent (CDT positive) RTs 
at higher proportions, such as RT126 (89% of the tested strains) and RT078 (50% of the tested strains). 
In contrast, in the previous Portuguese study, moxifloxacin resistance was not a common feature of 
RT078 isolates, and they were reported only in the last 2 years of the study (2014 and 2015) (Santos et 
al., 2016); in an Irish study, only 27.5% of the clinical isolates from RT078 were resistant to 
fluoroquinolones (Solomon et al., 2011). Results for RT126 is in agreement with an Italian study where 
the majority of the fluoroquinolone-resistant strains analysed belonged to RT126 (Spigaglia, Barbanti, 
Dionisi, & Mastrantonio, 2010).  Overall these results show that emergency of fluoroquinolone-resistant 
strains is dependent on the country, and suggest that an evolution towards the dissemination of more 
resistant strains in ongoing.  All resistant strains were tested for point mutations in the QRDR, of GyrA 
and a substitution Thr82Ile was found in all resistant isolates, while only one GyrB substitution 
(Ser416Ala) was found in one strain. However, this GyrB substitution is not associated with 
fluoroquinolone resistance, since it had already been observed in susceptible strains (Spigaglia et al., 
2008). 
There was no evidence for vancomycin resistance in our study. Decreased susceptibility for this 
antibiotic has been reported, but with reduced rates. In the pan-European study almost every strain was 
susceptible to vancomycin (96.84%) (Freeman et al., 2015); in a recently Portuguese study, two isolates 
had decreased susceptibility to vancomycin (0.4%) belonging to RT001 and RTAI-58 (Santos et al., 
2016). Therefore, this antibiotic remains the preferred treatment option for treating patients suffering 
from moderate to severe CDI and for those that do not respond to initial therapy with metronidazole 
(Debast et al., 2014). For metronidazole, only four strains were classified as resistant, three of them 
belong to RT027. Strains from this RT were also found to be resistant to metronidazole in the previous 
Portuguese survey (Santos et al. 2016) and among the 2.2% European metronidazole-resistant strains 
(Freeman et al., 2015). Notably, one of the patients harbouring the metronidazole-resistant strain was 
previously exposed to this antibiotic. Although no information was available for the others patients, with 
the usage of metronidazole for CDI treatment it is possible that they had been exposed to this antibiotic, 
as such, this phenotype could probably due to the selective pressure of the antibiotic usage. Moreover, 
because the susceptibility test was conducted by disk diffusion, it’s possible that the resistance rates 
were overestimated as some inhibition zone near the breakpoint may be inaccurately determined. 
Besides that, those putative resistant strains should be confirmed using the gradient diffusion by Etest® 
strips or even by agar dilution test as recommended by EUCAST guidelines (v.6.0; 
http://www.eucast.org), to confirm these results and get the exact MIC. 
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Rifamycin’s resistance was reported in a United States study with rates of 1.6% for paediatric 
isolates and 6.7% for adults isolates (Kociolek et al., 2016). In the pan-European study resistance 
frequency for rifampicin was 13.4%, however, with variable rates between countries (from 0 to 62.4%) 
(Freeman et al., 2015). In the current study, 11.5% of the tested strains were rifampicin-resistance, 
although lower than the overall European rate, was higher to those observed in the majority of the 
countries. Rifampicin resistance was detected in all RT017 isolates, as well as in a RT241 (1/2, 50%):  
two already know amino acid substitutions in RpoB were detect, His502Asn and Arg505Lys (Curry et 
al., 2009). However, a novel amino acid substitution (Ser507Leu) was observed in the only RT043 
resistant-strain found, which didn’t harbour any of the know mutations. Being therefore likely associated 
with this phenotype. Previous studies with Staphylococcus aureus and Mycobacterium tuberculosis have 
shown that independently derived mutations in these residues are frequently detected, being that an 
equivalent Serine to Leucine substitution was already describe for S. aureus resistant strains (Murphy 
et al., 2006; O’Connor et al., 2008). Resistance to rifampicin may compromise the use of rifaximin, 
considered an alternative therapy for relapsing CDI. (Curry et al., 2009; Debast et al., 2014).  
Imipenem resistance is not well documented in C. difficile. In the present study only RT017 
strains were resistant to imipenem. A Korean study also reported resistant for this antibiotic in RT017 
(12%), simultaneously with the introduction of the drug at the hospitals (Lee, Lee, Lee, Riley, & Kim, 
2014). In the pan-European study it was reported a 7.4% imipenem-resistance rate, but no distribution 
per RTs was described. Nonetheless, the geometric mean imipenem MICs were highest among RT027 
and RT106.  
In the present study, the distribution of resistance determinants for MSLB antibiotics (ermB 
gene) and for tetracycline (tetM gene) were highly variable between and within RTs. Overall, ermB gene 
was detected in only 10.1% of the strains tested; in a study conducted by Wasels, Spigaglia, Barbanti 
and Mastrantonio (2013) they reported a burden associated with the in vitro fitness in strains harbouring 
mobile elements containing the ermB-gene. This could be the explanation behind the low frequency of 
this gene in our study. 
Concerning the tetM gene, used to estimate tetracycline resistance strains, a low rate was 
observed (20.1%) as compared to a study conducted in China where tetM frequency reached 41.7% in 
RTs such as RT017, RT065, RT014, RT046 and RT002 (Dong et al. 2013). In our study, tetM was 
ubiquitous among RT017, RT126 and RT078, showing that it is associated with specific RTs, which 
may explain differences among studies. Most of the strains harboured the Tn916 transposon while a 
small fraction carried the Tn5397 element which is in agreement with other reports (Dong et al., 2013; 
Spigaglia et al., 2005). Of relevance, four tetM-positive strains were negative for those two transposons 
markers. Further studies should be carried on these strains using WGS in order to characterize putative 
novel tetM-carrying elements. Forty percent of the non-toxigenic strains tested harboured at least one 
resistance determinant (ermB or tetM), as such, it should be noted that these generally unnoticed strains 
could act as a pool of resistance determinants transmissible to toxigenic strains.  
The catD gene, which confers resistance to chloramphenicol, was not found in any of the strains 
tested; despite the small sample (n = 338), it can be speculated that this gene does not circulate in 
Portugal. The causes of the relatively low incidence of chloramphenicol-resistant C. difficile in the 
country are not known, although it’s conceivable that would be related to the local drug prescription 
habits. Accordingly, in the pan-European study, most prevalent RTs were largely susceptible (95–100% 
of isolates) to chloramphenicol. Clusters of chloramphenicol-resistant isolates were found only in 
Germany, The Netherlands and Latvia (Freeman et al., 2015).  
Aside from an European study were a set of multidrug resistant isolates were characterized 
(particularly belonging to RT001, RT012 and RT017) (Spigaglia et al., 2011), in the current study, the 
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most prominent multidrug resistant RT was RT017. Only one strain belonging to RT241 was also 
associated with multidrug resistance, harbouring the ermB resistance gene and mutations conferring 
resistance to moxifloxacin and rifampicin. In addition, when tested for further antibiotics, all RT017 
strains showed simultaneous resistance to six different classes of antibiotics. According to Coia (2009) 
the use of a particular antimicrobial agent could result in selective advantage for the spread of C. difficile 
if the organism is resistant to that particular drug. Therefore, it is tempting to suggest that multidrug 
resistance would be a good driver of CDI epidemics. Having that in mind, in the currently study, three 
different techniques (phenotypic characterization, MLVA and WGS) were used to characterize toxin 
A-negative/toxin-B-positive group of strains to which the multidrug resistant RT017 belongs. 
Twenty strains were tcdA-/tcdB+ of which, 19 belonging to RT017 and one to RT265. To date, 
there were no reports of RT265 strains in Portugal. According to van Dorp et al. (2017) this RT appears 
to be very uncommon or absent in North American and European countries, except for Belgium and the 
Netherlands being primarily isolated from children aged < 2 years. In our study, this RT was isolated in 
an elderly patient. WGS analysis showed that RT265 shares many features with RT017, such as: an 
intact tcdB gene, a 1.8 kb deletion in tcdA, and no genes of CDT genes, according to previous data (van 
Dorp et al., 2017). This strain also belonged to MLST clade 4 and was assigned toST88. Also, similarly 
to RT017, this RT contains a gene coding for a fifth HMW PBP. Overall, these indicates that these two 
RTs are close, although belong to different clusters by MLVA and SNPs analysis.   
Regarding C. difficile RT017, despite the loss of the capability to produce both toxins, this RT 
is increasingly becoming a potential epidemic strain, being isolated over the past decade in Asian as 
well as emerging in a few European countries (Arvand et al., 2009; Dobreva et al., 2013; Lee et al., 
2014; Yang et al., 2017). In the currently study, RT017 make up 5.1% of the isolates, which is pretty 
much similar to the five years study previously conduct in Portugal (Santos et al., 2016). It is worth 
noting that all the isolates found are either endemic, such as the ones found in hospital B, or associated 
with an outbreak, such as in hospital A (since all the isolates from that hospital remote from a short 
period of time, sharing the same molecular characteristics), with no single cases found, showing the 
virulence and epidemics of these strains. 
As already mentioned above, resistance was found for moxifloxacin, rifampicin and imipenem, 
plus the presence of tetM gene for all the strains and ermB in hospital B isolates. Those RT017 strains 
were also tested for antibiotic susceptibility for other drugs; as result, all of the isolates in the present 
study were susceptible to chloramphenicol and tigecycline and resistant to tetracycline. Interestingly the 
presence of tetM gene in all strains seems to have an effect on tetracycline susceptibility but not to 
tigecycline (a tetracycline derivative antibiotic), probably because this third generation drug display 
enhanced antimicrobial activity overcoming ribosome protection mechanisms as the one promoted by 
tetM (Dönhöfer et al., 2012). 
All RT017 isolates also had high-level erythromycin and clindamycin-resistance, including the 
hospital A strains classified as ermB-negative; for those strains the ermG gene was found by WGS 
analyses. This ermG gene encodes for an rRNA adenine N-6-methyltransferase, which can methylate 
adenine at position 2058 of 23S rRNA, conferring resistance to MLSB antibiotics. This gene has 
appeared in human colonic Bacteroides species where it was found on conjugative transposons 
(Shoemaker, Vlamakis, Hayes, & Salyers, 2001; Wang et al., 2003). Although, the results presented 
here do not prove that DNA was transferred directly from these species to C. difficile, the data indicates 
that this gene was transferred by a mobile element; Wasels et al. (2014) have already provides evidence 
of the possible transmission of antibiotic resistance determinants among pathogenic bacteria occupying 
the same human intestinal niche, which may have happened in that case. In C. difficile the presence of 
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ermG gene was previously reported in one non-toxigenic strains (RT009), but without any phenotype 
associated (Pereira et al., 2016). 
The ermG gene was shown to be associated with high level of resistance to clindamycin and 
erythromycin, through transformation of C. difficile 630Δerm with a plasmid containing ermG. Despite 
its previous occurrence in a non-toxigenic strain, this is the first time it is described in toxigenic strains, 
and associated with a resistance phenotype. Its presence only in the strains belonging to hospital A may 
be indicative of recent gene transfer, highlighting the importance of an active surveillance of resistance 
determinants.  
Since ermG is located in a mobile element, there is the possibility to spread via horizontal gene 
transfer. The ermB-negativity in high-level MSLB-resistant isolates is a well-known phenomenon (Nyc 
et al., 2016; Spigaglia et al., 2011), and therefore it can be speculated if some of these reported strains 
harboured the ermG gene. Further studies should be also carried to understand if the carriage of the 
element containing the gene would have fitness cost associated.  
The presence of mefA and the msrD genes were also observed in this mobile element; those two 
genes are known to promote low or moderate levels to macrolide resistance by active efflux of the 
antibiotic, due to an efflux pump that belongs to the major facilitator superfamily encoded by the mefA 
gene, or by an efflux protein belonging to the ABC transporter superfamily encoded by msrD. The msr 
group differs from the mef genes because it confer resistance to both macrolide and streptogramin B 
antibiotics, although for both, clindamycin is neither an inducer or a substrate for the pump, and thus 
the strains caring those genes are fully susceptible to this antibiotic (Leclercq, 2002; Metcalf et al., 
2017). Since the RT017 strains had high-level resistance to the later antibiotic, we confirm that these 
genes don’t have a role in resistance. In addition, the presence of mefA and the msrD genes could only 
explain low or moderate resistance levels to macrolides or streptogramin B, again emphasizing the role 
of ermG. 
These results indicate that our real MLSB-resistance rate must be higher than the one deduced 
from the frequency of the ermB gene, since other mechanisms can be involved; therefore, all strains 
should be tested for antibiotic susceptibility to identify the resistant strains, and then the associated 
genetic determinants should be characterized. As reported by the European Centre for Disease 
Prevention and Control (2016), MLSB antibiotics are one of the most common drugs used in both 
community and hospital sector in Europe, what makes really important to keep track on the resistance 
patterns for these group of antibiotics. 
The putative mobile element also contained a gene encoding a streptogramin A 
acetyltransferase. This protein belongs to the large family of virginiamycin O-acetyltransferase (Vat) 
enzymes, known to cause resistance to the streptogramin A antibiotics (Stogios et al., 2014), however 
this group was not tested here, hence, its potential impact in antibiotic susceptibility of those C. difficile 
strains is unknown.  
Concerning imipenem resistance, mutations in HMW PBP genes were found in all RT017 
resistant strains, as in an earlier study where RT017 collected between 2012–2015 carried mutations in 
PBPs and showed statistically higher imipenem MIC than the isolates with no mutations (Isidro et al., 
2017). In that study two mutations (at pbp1 and pbp3) were thought to be causative of resistance, 
although, in the current study all the resistant strains from hospital A harboured only mutations in pbp3 
(Figure 3.3 B). So, it’s legitimate to speculate if this single mutation is the one crucial for resistance. 
Yet those results show clearly that the interpretation of such data is not going to be straightforward, and 
more studies need to be done. Portugal has been one the major consumers of carbapenems in the hospital 
sector in Europe (European Centre for Disease Prevention and Control, 2016), as Dingle et al. (2017) 
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associated RT027 fluoroquinolone-resistant emergency with fluoroquinolone use, it’s conceivable to 
conclude that the emergence of carbapenems resistance in C. difficile is likely due to the high usage of 
this class of antibiotic in the recent years, highlighting the importance of a responsible use of antibiotics. 
MLVA was performed for RT265 and RT017 strains. Minimum spanning tree analysis clearly 
demonstrate the genetic relationships among the RT017 Portuguese isolates being possible to identify 
five clonal clusters. Furthermore, the fact that a group of isolates were collected from the same hospital 
within a 6-years period, suggests that this degree of similarity among MLVA types is highly indicative 
of nosocomial transmission and persistence of the same clones over the years.  
The VNTR loci used in this study were previously demonstrated to be useful for epidemiologic 
investigation of C. difficile outbreaks and nosocomial transmission (Marsh et al., 2006); their utility for 
detection of outbreaks was demonstrated by analysis of a group of RT017 from hospital A which 
clustered on the same branch of the minimum-spanning tree indicating a genetic relatedness among 
these isolates. 
Previous studies using MLVA have demonstrated genetic relatedness among a large collection 
of tcdA-/tcdB+ strains from seven countries (van den Berg et al., 2004). In this study, RT265 revel to be 
distance from the others analysed strains, consistence with the fact it belongs to a different RT.  
In summary, the MLVA results indicate that INSARJ’s isolates collection consists primarily of 
three major complexes of highly related isolates, suggestive of hospital-acquired infections. 
A phylogenetic tree of SNPs identified through WGS analyse revealed two main related groups 
comprising 33 RT017 clinical isolates that distinguish the imipenem-resistant strains from the 
susceptible ones. Nevertheless, it was possible to distinguish the local RT017 isolates from the 
international control strain (C. difficile M68). Overall, 74 SNPs were found which includes variants 
between the clinical strains and the reference in sequences that have an ortholog to a known gene 
sequences, and 22 of these variant sites were able to discriminate the isolates from this work belonging 
to hospitals A and B, from the previous isolates, collected from hospitals B and C. 
Among this 22 SNPs variations there was a series of non-synonymous mutations in important 
genes, including genes involved in the metabolism and antibiotic resistance, mutations leading to 
truncated proteins were observed for a hypothetical protein, a transcriptional regulator and 
SAM-dependent methyltransferase, the last one associated to diverse metabolic functions in biocatalysis 
and biosynthesis (Struck, Thompson, Wong, & Micklefield, 2012); the meaning of these findings has to 
be studied in future works. The high number of SNPs found in hypothetical proteins is also very 
interesting, and this group should be further studied to predict their function and the effect of the point-
mutations found in some of them. 
Remarkably, the most recently strain and one of the most ancient strain from hospital B, 
separated by a period of 6-years, had only 4 SNPs distance, what is consistent with the evolutionary 
mutation rate estimated by Eyre et al. (2013) of 0.74 SNPs per year, suggesting that the isolates share a 
common ancestor. This result supports the idea that a clonal strain from RT017 is endemic in hospital 
B, persisting for at least 6-years leading to nosocomial transmission. Further studies are needed to 
investigate the persistence of these strains in the hospital setting. 
WGS results also suggest that the clonal strains persisting in hospital B is different from the 
hospital A strains. Additionally, all the isolates from hospital A were tight closely, reinforcing that an 
outbreak has occurred. How this outbreak clonal strain was inserted in the hospital remains unclear, but 
it could be due a patient that was infected in the community and spread the strain during its hospital 
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stay, which raises many concerns especially on the spread of this multidrug resistant strain in the 
community. 
In conclusion, the current work gives a contribution to the knowledge of the molecular 
epidemiology and resistance patterns of C. difficile in Portugal, especially of the emergent strains of 
RT017, which are multiresistant and associated with endemic or epidemic cases of CDI. A new 
resistance determinant, found in a mobile element, was characterized for the first time in C. difficile 
toxigenic strains. The results also suggest that the lineage of strains from RT017 appears to be constantly 
evolving, acquiring new resistance determinants, which highlights the need for continued 
epidemiological and antimicrobial surveillance. Finally, this work provides the foundation for future 
studies, namely the role in RT017 evolution of SNPs found in several proteins, including many 
hypothetical ones; to study the spread and impact on the fitness of the new mobile element, as well as 
to assess whether this element can be easily transferred among clinical strains, from the same or different 
RTs, by horizontal gene transfer. 
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7. Supplementary information 
Supplementary table 1. Multilocus variable number tandem repeat analysis profiles for 
Clostridium difficile tcdA-/tcdB+ isolates.  
Isolate / Loci  A6Cd B7Cd C6Cd E7Cd G8Cd CDR60 
A1 29 15 27 10 18 10 
A2 2 11 20 8 32 8 
A3 2 11 21 8 32 8 
A4 2 11 21 8 32 8 
A5 2 11 21 8 32 8 
A6 2 11 20 8 32 8 
A7 2 11 20 8 32 8 
A8 2 11 15 8 32 8 
A9 2 11 15 8 32 8 
A10 2 11 15 8 36 8 
A11 2 11 15 8 32 8 
A12 2 11 15 8 32 8 
B1 2 8 21 8 36 7 
B2 2 8 24 8 35 8 
B3 2 9 28 8 33 8 
B4 2 10 21 8 32 7 
B5 2 10 21 8 35 7 
B6 2 9 21 8 36 7 
B7 2 10 24 8 34 7 
B8 2 9 21 8 35 7 
B9 2 10 23 8 35 7 
B10 2 8 24 8 34 7 
B11 2 8 23 8 34 7 
B12 2 8 15 8 35 7 
B13 2 10 23 8 40 7 
B14 2 8 23 8 33 7 
B15 2 9 23 8 36 7 
B16 2 8 23 8 35 7 
B17 2 8 21 8 31 7 
B18 2 10 24 8 34 7 
B19 2 10 21 8 36 7 
B20 2 9 23 8 36 7 
B21 2 10 25 8 34 7 
B22 2 9 28 8 33 7 
B23 2 9 28 8 34 7 
B24 2 9 24 8 36 7 
B25 2 9 24 8 36 7 
B26 2 8 24 8 35 7 
B27 2 9 27 7 34 7 
B28 2 8 24 8 35 7 
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Supplementary table 1. continued page 2 of 2 
Isolate / Loci  A6Cd B7Cd C6Cd E7Cd G8Cd CDR60 
B29 2 8 21 8 31 7 
B30 2 9 28 8 34 7 
B31 2 9 29 8 33 7 
B32 2 9 27 8 33 7 
B33 2 9 28 8 33 7 
B34 2 9 27 8 33 7 
B35 2 10 25 8 34 7 
C1 2 8 18 8 3 6 
C2 2 8 18 8 31 6 
C3 2 8 18 8 31 6 
 
 
 
 
 
 
 
 
 
 
